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Ovarian cancer, it is believed, results from the dysregulation, in normal ovarian epithelial 
cells, of genes responsible for the control of critical biological processes such as cell 
cycle and apoptosis. Since their discovery 20 years ago, microRNAs (miRNAs) have 
increasingly been implicated in that dysregulation due to their role fine-tuning gene 
expression. As a result, changes in expression levels of microRNAs have been linked 
with tumor growth, proliferation and metastasis. Their imputed involvement in cancer has 
led to the possibility of their use as biomarkers and to their potential clinical use. But the 
use of miRNAs as therapeutics requires accurate predictions of their direct mRNA targets 
and additional knowledge concerning subsequent downstream effects. Since our current 
apprehension of the effects of variations in miRNA expression levels is far from 
complete, the therapeutic value of microRNAs is somewhat limited. Using a combination 
of mRNA and miRNA microarray analysis to compare human gene expression between 
normal epithelial ovarian cells (OSE) and epithelial ovarian cancer (EOC) cells, we 
explored the interactions among miRNAs and genes. First, we validated in silico 
predictions of mRNA targets of microRNAs by comparing them with in vitro evidence 
after exogenous miRNA transfection. We found that miRNAs with identical seed regions 
shared 88% of their predicted targets, and 55% of their in vitro targets, confirming the 
importance of their 7-mer seeds. Importantly, we found that even small changes in the 
seed region resulted in significant changes in the set of mRNAs targeted, implying strong 
functional conservation of the seeds. 
 
 xiii 
Next, we discovered a 3-element network motif which explains the upregulation of ~800 
genes in ovarian cancer which, as predicted miRNA targets, might be expected to be 
down-regulated. This motif also revealed a competition, of sorts, between the repressive 
action of highly regulated microRNAs and the derepressive influence of down-regulated 
transcription factors 
Finally, we developed a phenomenological network model, based on the Pearson 
correlation of high-throughput microarray gene expression data, to identify specific 
dysregulated modules involved with cell cycle and apoptosis. Our methodology identified 
several genes previously reported in ovarian cancer and, significantly, suggests some 
additional genes for further study. This technique can easily be extended to reveal 




 CHAPTER 1 
INTRODUCTION 
Background 
The notion that cancer might be better understood on the basis of genetic mutations was 
suggested by the early successes of the gene-centric approach to disease in the 20th 
century, which found, e.g., associations linking cystic fibrosis with mutations in the 
CFTR gene, muscular dystrophy with mutations in the dystrophin (DMD) gene, and 
sickle cell anemia with gene mutations in HBB (hemoglobin, beta). The discovery, in 
ovarian cancer, of mutations in KRAS, BRAF (Singer, Oldt et al. 2003) and other driver 
(and the more numerous but somewhat less pernicious passenger) genes (Haber and 
Settleman 2007), led to the expectation that the replacement or repair of a few miscopied 
bases, or the inhibition of a few key overactive RTKs (receptor tyrosine kinases, e.g., 
EGFR, FGFR, PDGFR) or their cognate growth factors, might halt the metastatic 
progress of, or at least inhibit the rapid growth of, the majority of solid cancers. But 
reaching, perhaps, the limits of reductionism in medicine (Ahn, Tewari et al. 2006), 
scientists have expanded this somewhat narrow perspective to a broader, more holistic 
view of biological process dysregulation, which increasingly recognizes, first, a greater 
variety of biological elements, from non-coding ribonucleic acids and proteins to lipids 
and metabolites, and second, the importance of the construction and interpretation of an 
interactome (Vidal, Cusick et al. 2011), a network of biological elements and their 
mutually influencing/interacting relationships. Among non-coding ribonucleic acids, both 
long (lncNRA) and short (miRNA) transcripts have become the subjects of increasing 
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interest. Specifically, the diagnostic, prognostic and therapeutic value of miRNAs is 




What are miRNAs, and what makes them biologically relevant in cancer? MiRNAs are 
short (~22-nt) non-coding RNA sequences first reported, in animals, to be involved in 
larval development in C. elegans (Lee, Feinbaum et al. 1993). Similar RNA interference 
had been seen in plants three years earlier (Napoli, Lemieux et al. 1990). By 2004, it was 
believed miRNAs might regulate up to 10% of human genes. Today, it is known that 
miRNAs regulate gene expression by binding and repressing mRNAs post-
transcriptionally. In eukaryotes, each miRNA binds to a specific location in the 3’UTR of 
a targeted mRNA with a conserved 7-nt seed region (often, positions 2-8) and inhibits 
translation by causing mRNA destabilization and degradation (Bartel 2009). When 2 or 
more miRNAs have an identical seed region, they are said to belong to the same family. 
Since most human genes have binding sites for more than one family, in addition to 
multiple binding sites for each family, complex relationships emerge between cell type, 
miRNAs and gene targets. The resulting gene repression is reflected in the observed 
down-regulation of predicted miRNA targets in microarray assays. 
MiRNA dysregulation has been associated with many diseases, notably cancer (Miles, 
Seiler et al. 2012). Thus, knowledge of the 7-nt seed sequences for the 1100 currently 
known (though not necessarily conserved) human miRNAs (Betel, Koppal et al. 2010), 
and a global census of mRNA binding sites, are critical to the successful application of 
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miRNAs in a clinical setting. However, since our knowledge of the downstream effects 
of exogenous miRNA transfection is incomplete, the therapeutic value of miRNAs is 
necessarily limited. We investigated two issues relating to the relevance of miRNAs in 
cancer. 
In Chapter 2, we look at seed region variation, and confirmed the unique properties of the 
7-nt (nucleotide) seed. Using observations from wet lab experiments, we verify that 
miRNAs with identical 7-mer seeds target a similar subset of genes. More importantly, 
we found that miRNAs whose seeds differ by just a single nucleotide (nt) target 
substantially different genes; the overlap of miRNAs with similar (but not equivalent) 
seeds is ~20%. Curiously, the average target overlap for two randomly chosen miRNAs 
is also about 20%. The fact that a single nt seed change has such a radical effect on the 
miRNA target population results in strong evolutionary pressure to preserve seeds, and 
helps explain the existence and conservation of miRNA families. 
In Chapter 3, we present a novel model called TOM (Transcriptional Override Model) 
which accounts for the unexpected upregulation, in cancer, of many genes which were 
predicted targets of upregulated miRNAs. The mechanics of gene repression via miRNA 
inhibition anticipate an inverse relationship between (rising) miRNA expression and the 
(falling) expression of predicted mRNA targets. However, previous studies have found 
that less than 20% of computationally predicted mRNA targets are inversely related to 
their upregulated targeting miRNAs (Shahab, Matyunina et al. 2011). In contrast, using 
three computational prediction programs and the results of high throughput microarray 
experiments, we showed that the number of down-regulated miRNA targets in our cancer 
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samples were, in fact, significant. Importantly, using TOM, we were able to explain the 
unexpected upregulation of nearly 800 miRNA targets. 
Inconsistent genes 
Our work with miRNAs revealed the complexity and interconnectedness of miRNA-
repressor-mRNA relationships, and suggested a network approach to better understand 
gene-to-gene interactions. By building phenomenological network models comparing 
correlations between millions of pairs of genes in normal and cancerous ovarian epithelial 
cells, we found that the number of highly correlated genes decreased dramatically 
between normal and cancer tissues, implying a loss of control in cancer. Assessing 
pairwise gene-to-gene relationships in a boolean-like manner, we noticed that most gene 
pairs maintained a similar, consistent relationship between normal epithelial cells and 
cancer tissue. Gene pairs which did not maintain a similar relationship between normal 
and cancer, we termed inconsistent. We found that inconsistent gene pairs tended to 
share a number of important characteristics: one of the genes was generally upregulated; 
both genes were enriched for the cell cycle and/or apoptotic processes; and usually, at 
least one member of an inconsistent gene pair was previously implicated in ovarian 
and/or other cancers. The complexity of these highly interconnected network modules 
suggests, contrary to popular opinion, that there are no master regulators of cancer. 
Instead, we believe there exists an orchestra of cancer-related genes, a few hundred at last 
count (Forbes, Bindal et al. 2011) which, when altered through mutation and interacting 
in small ensembles, can disrupt critical biological processes such as cell cycle and 
apoptosis (Kerr, Wyllie et al. 1972) the dysregulation of which is a prerequisite for tumor 





FUNCTIONAL AND EVOLUTIONARY SIGNIFICANCE OF 




MicroRNAs have emerged in recent years as important regulators of cell function in both 
normal and diseased cells. miRNAs coordinately regulate large suites of target genes by 
mRNA silencing via degradation and/or translational inhibition. The mRNA target 
specificities of miRNAs in animals are primarily encoded within a 7 nt “seed region” 
mapping to positions 2-8 at the molecule’s 5' end. We here combine computational 
analyses with experimental studies to explore the functional significance of sequence 
variation within the seed region of human miRNAs. The results indicate that a 
substitution of single nucleotides at any position within the seed region changes the 
spectrum of mRNA targets by >70%. The high functional cost of even single nucleotide 
changes within seed regions accounts for their high sequence conservation among 
miRNA families both within and between species and sheds light on the mechanisms 
underlying the evolution of miRNA regulatory control. 
Author Summary 
MicroRNAs (miRNAs) are an important component of regulatory systems that are 
disrupted in many human diseases including cancer. The fact that many miRNAs are 
sequentially highly conserved between species seems inconsistent with the fact that their 
regulatory targets can be highly divergent. We present here complimentary computational 
and experimental evidence that even a single nucleotide substitution at any position 
within the “seed” region of miRNAs has major functional consequences on the regulation 
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of hundreds of target genes. These findings account for the high sequence conservation of 
miRNA seed regions among and between species (stabilizing selection). Additionally, the 
results suggest an evolutionary model whereby miRNA regulatory evolution is driven by 
the relatively rapid loss and/or gain of miRNA target sequences in regulated messenger 
RNAs. Consistent with this evolutionary model, we show that human and mice miRNAs 
with identical seed sequences nevertheless display <40% overlap in their regulated genes. 
  
Introduction 
MicroRNAs (miRNAs) are small 20-22 nucleotide (nt) RNA molecules that play 
important regulatory roles in cell function (Nazarov, Reinsbach et al. 2013), embryonic 
development (Alvarez-Garcia and Miska 2005) and the onset and progression of a variety 
of diseases (Ha 2011), including cancer (Nana-Sinkam and Croce 2010). Like siRNAs 
and other small regulatory RNAs, miRNAs regulate their target genes by mRNA 
degradation and/or translational inhibition (Bartel 2004). However, unlike siRNAs that 
target one or a few genes, individual miRNAs have evolved the ability to coordinately 
regulate large suites of target genes, many of which may encode coordinated cellular 
functions (Bartel 2004; (Shahab, Matyunina et al. 2011). The mRNA target specificities 
of miRNAs in animals are primarily encoded within a 7 nt “seed region” mapping to 
positions 2-8 at the molecule’s 5' end (Bartel 2009; (Wang 2014). The importance of this 
7 nt sequence to miRNA function is evidenced by the fact that the seed region sequence 
of many miRNA families is highly conserved both within and between species 
(Friedman, Farh et al. 2009). Mature single-stranded miRNAs bound to the RNA-induced 
silencing complex (RISC) recognize their regulatory targets by Watson-Crick base 
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pairing to compatible sequences (usually in 3' un-translated regions or 3' UTRs) in target 
mRNAs.   
It is estimated that there are >1800 sequentially distinct miRNAs in the human genome, 
each being present in a few to hundreds of copies (Kozomara and Griffiths-Jones 2014). 
We focused on 249 human miRNAs previously shown to be sequentially conserved 
across mammalian species (Lewis, Shih et al. 2003). In this study, we combine 
computational analyses with experimental studies to explore the functional significance 
of sequence variation within the seed region of human miRNAs. We find that a 
substitution of only a single nucleotide at any position within this 7-nt region alters the 
spectrum of targeted mRNAs by >70%.  Further nucleotide changes have little to no 
additional effect. This high functional cost of even a single nucleotide change within the 
seed region of miRNAs explains the rigidly conserved seed sequence identity among 
many miRNA families both within and between species and sheds light on likely 
mechanisms underlying the evolution of miRNA regulatory control. 
 
Results and Discussion 
We first computed the number of nucleotide changes needed to transform one seed region 
into another using the Hamming distance (Hamming 1950) for each of these 249 
miRNAs. We then calculated the percent overlap (cosine similarity (Tan, Steinbach et al. 
2005)) of predicted targets for all pairs of these 249 miRNAs having identical seeds. For 
example, the percent target gene overlap for miR-25 and miR-32 (both having the seed 
sequence: 5'AUUGCAC) predicted by the miRanda- mirSVR (Betel, Koppal et al. 2010) 






Figure 2.1: A single nucleotide difference in the seed region of miRNAs is associated 
with a major change in regulated target genes. a) MiR-25 and miR-32, two miRNAs 
with identical seed regions (upper-case letters), have 81% overlap in their predicted target 
genes; b) MiR-25 and miR-183, two miRNAs with a single nucleotide difference within 
their respective seed regions have only 18% overlap in their predicted target genes; c) 
The overlap of predicted targets for all 249 pairs of conserved miRNAs grouped by the 
number of mismatches in their respective seed regions.  The computed percent overlaps 
(cosine similarity) are presented as box and whisker plots [the bottom and top of each 
box represent the first and third quartiles of variation while the band inside the box 
represents the median (second quartile) value; the “whiskers” represent variability 
outside the upper and lower quartiles]; d) Four members of the miR-200 family  (miR-
141, miR-200b, miR-205, miR-429) and a negative control were independently 
transfected into HEY cells and, after 48 hrs, RNA was extracted and subjected to gene 
expression analysis (Affymetrix, U133).  The histogram displays the observed overlap of 
all significantly differentially expressed genes (light shading) between miR-429 
transfected cells and cells transfected with miR-200b (identical seed region with 
miR429), miR-141 (1 seed region mismatch with miR-429) or miR-205 (5 seed region 
mismatches with miR-429). Shown also (dark shading) is the percent overlap between 
significantly down-regulated mRNAs that are predicted targets of the transfected 
miRNAs.  
 
The median percent overlap between all 249 pairs of conserved miRNAs with identical 
seeds is 88% (Figure 2.1c). We next independently computed the percent overlap of 
predicted mRNA targets for pairs of miRNAs having seeds that differed by 1 to 7 
nucleotides. The results (Figure 2.1b, 2.1c) demonstrate that even a single nucleotide 
mismatch in the seed regions of two miRNAs is predicted to reduce the percent overlap 
among their respective targeted mRNAs by >70%. The generality of these predictions 
was corroborated independently by conducting the same analyses using two additional 
target prediction algorithms (TargetScan (Friedman, Farh et al. 2009) and PicTar (Krek, 
Grun et al. 2005)). 
 
To experimentally test these predictions, we selected members of the miR-200 family of 
human miRNAs that share identical seed regions (miR-429 vs. miR-200b), differ by a 
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single nucleotide (miR-429 vs. miR-141) or differ by multiple nucleotides (e.g. 5 
nucleotide differences: miR-429 vs. miR-205) within their respective seed regions 
(Figure 2.1d). These miRNAs, as well as, a synthetic control miRNA with no sequence 
homology to any known miRNA were independently transfected into the well 
characterized ovarian cancer HEY cell line (Buick, Pullano et al. 1985) and, after 48 hrs, 
RNA was extracted and subjected to gene expression analysis (Affymetrix, U133) as 
previously described (Shahab, Matyunina et al. 2012; (Jabbari, Reavis et al. 2014) (see 
Tables A.1, A.2, A.3 and A.4 for detailed results of microarray analyses). 
 
Ectopic over-expression of miRNAs in cells induces both direct and indirect changes in 
gene expression (Shahab, Matyunina et al. 2011) while target prediction algorithms only 
predict direct interactions, i.e. mRNAs predicted to be directly targeted by specific 
miRNAs. Thus, from our experimental dataset, we were interested in comparing those 
down-regulated mRNAs predicted by miRanda-mirSVR to be targeted by the miRNAs 
employed in our transfection experiments. As in the computational analyses, we 
computed the percent overlap between genes significantly down-regulated in response to 
transfection of miRNAs having identical seeds, seeds with a single nucleotide difference 
and seeds with 5 nucleotide differences (Figure 2.1d). The remarkable concordance 
between the computationally predicted and experimentally observed results corroborates 
the hypothesis that even a single nucleotide difference within the seed region of miRNAs 




We were next interested in determining if the position of single nucleotide changes 
within the seed region of miRNAs has a significant effect. Drawing again on the 
miRanda-mirSVR target predictions of the 249 sequentially conserved miRNAs, we 
divided pairs of miRNAs whose seeds differed by a single nucleotide into separate 
groups based on the position (positions 2-8) of the mismatch within their respective seed 
regions. The results presented in Figure 2.2a display the percent overlap of predicted 
mRNA targets among miRNAs differing by a single nucleotide at different positions 
within their respective seed regions. The results indicate that a mismatch at any position 
within the seed region is predicted to result in the same significant reduction in overlap 
relative to a perfect 7 nt match. 
 
To experimentally test the effect of the position of single nucleotide differences within 
seed regions on targeted mRNAs, we constructed a synthetic miRNA identical in seed 
sequence to miR-429 (and miR-200b) but for a single nucleotide change at position 2 
(M12). The naturally occurring miR-141 is also identical in seed sequence to miR-429 
but for a single nucleotide change at position 4 (Figure 2.2b). These miRNAs (and the 
negative control) were independently transfected into HEY cells and, after 48 hrs, RNA 
was extracted and subjected to gene expression analysis (Affymetrix, U133). The results 
presented in Figure 2.2b (see Tables A.1, A.2, A.3 and A.5 for detailed microarray results) 





Figure 2.2: Single nucleotide changes at any position within the seed region of 
miRNAs are associated with a major change in regulated target genes. a) Shown is 
the percent overlap (cosine similarity) of predicted mRNA targets among 30,876 pairs of 
miRNAs differing by a single nucleotide at different positions within their respective 
seed regions. b) mir-429, miR-200b, miR141 and a synthetic miRNA identical in 
sequence to miR-429 but for a single nucleotide change at position 2 (M12) (and negative 
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control) were independently transfected into HEY cells.  The histogram displays the 
observed overlap of all significantly differentially expressed genes (light shading) 
between miR-429 transfected cells and cells transfected with miR-200b (identical seed 
region with miR429), miR-141 (1 seed region mismatch at position 4) and M12 (1 seed 
mismatch at position 2). Shown also (dark shading) is the percent overlap between 




The above results indicate that even a single nucleotide substitution within the seed 
regions of miRNAs results in large changes in target mRNAs and consequentially altered 
global patterns of gene expression. These findings further imply an evolutionary model 
whereby strong stabilizing selection is maintaining rigid conservation of miRNA seed 
sequences both within and between species. Individual target genes, on the other hand, 
may acquire and/or lose miRNA regulatory control(s) through even single nucleotide 
substitutions in miRNA target sequences complimentary to miRNA seeds (typically 
within 3' UTRs) (Figure 2.3). Any functional consequence of such mutations would be 
incurred on the individual gene level rather than on the multi-gene level associated with 
miRNA seed region mutations. Thus, the model predicts that although seed regions may 
be highly conserved both within and between species due to strong stabilizing selection, 
the spectrum of genes regulated by these conserved miRNAs may vary significantly, 
especially between more distantly related species where there has been ample 
time/opportunity for individual genes to acquire variations in their target sequence(s) and 
to re-associate themselves with other, presumably adaptive, miRNA regulatory controls 




 Figure 2.3: The high functional cost of even single nucleotide changes in miRNA 
seed regions implies a mechanism of miRNA regulatory evolution.  
 
 
To test this prediction, we selected two miRNAs (miR-429 and miR-200b) that have 
identical seed regions in both humans and mice (Figure 2.4a). We again employed the 
miRanda-mirSVR algorithm to predict the respective orthologous mRNA targets of these 
two miRNAs (human: hsa-miR-429, hsa-miR-200b; mouse: mmu-miR-429, mmu-miR-
200b) in both species. As shown in Figure 2.4b, the percent overlap between the 
predicted gene targets of these two miRNAs (intra-specific) is >90% (mouse: 93.3%; 
humans: 91.8%) in both species.  However, despite the fact that the human and mouse 
miRNAs share sequentially identical seed regions, they display < 40% overlap among 
their respective target genes/mRNAs in the non-native species (inter-specific)  (Figure 
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2.4b). To determine if these differences are representative of other sequentially conserved 
miRNAs, we computed the percent overlap of genes targeted by the 249 miRNAs 
sequentially conserved in mouse and humans. The results confirm that the average 
overlap between targeted genes in mouse and humans is < 30% (Figure 2.4c). These 
results are consistent with the hypothesis that while miRNA seed regions may be 
selectively conserved across species, target genes maintain relative flexibility to acquire 
or lose miRNA regulatory controls by even single nucleotide changes within their 




Figure 2. 4: Although mouse and human miRNAs share sequentially identical seed 
regions, they regulate highly divergent groups of target genes. a) Sequence alignment 
between human (has-miR-429/200b) and mouse (mmu-miR-429/200b) miR-429 and 
miR-200b miRNAs. Despite the evolutionary distances between these two species, the 
respective seed regions are sequentially identical, reflective of strong stabilizing 
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selection. b) Venn diagrams showing the % overlap between human and mouse orthologs 
that are predicted targets (miRanda-mirSVR) of human and mouse miR-429 and miR-
200b. c) The average percent overlap of genes targeted by all 249 sequentially conserved 
mouse and human miRNAs is < 30%. The results are consistent with a model of 
directional selection operating on variation in miRNA target sequences (typically 




Collectively, our findings indicate that miRNAs initially evolve to regulate large suites of 
target genes. Thereafter, the sequential integrity of miRNA seed regions is maintained by 
strong stabilizing selection due to the high functional cost of even a single nucleotide 
mutation at any position within the miRNA. In contrast, nucleotide mutations in the 
target sequences of individual genes, being of substantially lower functional cost, allow 
for a relatively rapid repositioning of miRNA-target gene associations. Indeed, a variety 
of scenarios might arise to buffer the possible negative effects of target sequence 
mutations in regulated genes. For example, duplication of specific target sequences 
within regulated genes could serve to mask the impact of the sudden loss of existing 
miRNA regulatory controls while permitting genes to explore the potential adaptive 
benefits of acquiring new miRNA regulatory controls.  
 
Materials and Methods 
Cell culture and transfections 
HEY ovarian cancer cells, provided by Gordon B. Mills (MD Anderson Cancer Center, 
Houston, TX), were cultured in RPMI-1640 (Mediatech, Manassas, VA) with 10% Fetal 
Bovine Serum (FBS, Atlanta Biologicals, GA) and 1% antibiotic-antimycotic solution 
(Mediatech-Cellgro, Manassas, VA) and incubated at 37°C and 5% CO2. The transfection 
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protocol was as described described (Shahab, Matyunina et al. 2012; (Jabbari, Reavis et 
al. 2014). Briefly, triplicate wells of exponentially growing cells were transfected with 
miR-141, miR-200b, miR-429, miR-205 and M12 miRNAs purchased as Pre-miR™ 
miRNA Precursors (Ambion, Austin, TX). Transfections were performed using 
Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA) according to the 
manufacturer's instructions. Ambion Pre-miR™ miRNA Precursor Negative Control was 
used as a negative control. 
 
miRNA target prediction 
Predicted miRNA targets (mRNAs) were established using the miRanda-mirSVR (Betel, 
Koppal et al. 2010) target prediction algorithm (mirSVR score ≤-0.2). Corroborative 
predictions were carried out using the Targetscan (Friedman, Farh et al. 2009) and PicTar 
(Krek, Grun et al. 2005) prediction algorithms. 
  
RNA isolation and whole genome microarray 
RNA was extracted from transfected cells using RNeasy Mini RNA isolation kit 
(QIAGEN, Valencia, CA). Microarray experiments were performed as previously 
described (Shahab et al. 2012). Briefly, RNA samples with high integrity were converted 
to cDNA and amplified with Applause 3’-Amp System (NuGen, San Carlos, CA). The 
cDNA was fragmented and Biotin labeled using the Encode Biotin Module (NuGen). 
Labeled cDNA was then hybridized to Affymetrix HG-U133 Plus 2.0 arrays and 
analyzed with GeneChip Scanner 3000 (Affymetrix, Santa Clara, CA). All microarray 
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data are deposited in the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov) 
SuperSeries number GSE56973. 
 
Microarray data analysis 
Determination of differential expression of genes after transfection was carried out as 
follows: 1) normalization by Microarray Suite 5.0 (MAS5.0) using the Affymetrix 
Expression Console v1.1 to obtain present/absent calls. Probesets with less than 50% 
present calls across all samples were removed; 2) quality control and normalization by 
GC Robust Multi-array Average (GCRMA) as implemented by Array Analysis (Eijssen, 
Jaillard et al. 2013) to obtain expression values for experimental and negative controls. 
Using only those CEL files that passed quality controls, we calculated mean signal values 
for triplicate samples for miR-429, miR-200b, miR-205 and M12 (duplicate for miR-141) 
and negative control. The log ratio representing the change in expression between 
experimental miRNA and negative control transfections was calculated; 3) calculation of 
signal-to-noise ratio (SNR = mean/standard deviation) was used to select the probe set 
with the highest SNR. This guarantees the highest signal change while minimizing noise; 
and 4) multiple testing correction was done using SAM  (Significance Analysis of 
Microarrays (Tusher, Tibshirani et al. 2001)) with a false discovery rate (FDR) < 2%. 
 
miRNA target overlap 
Target overlap between  miRNAs was determined using cosine similarity (Tan, Steinbach 
et al. 2005) and as follows: the total number of overlapping genes was divided by the 




Orthologous genes in human and mouse were extracted using the BioMart data-mining 









TRANSCRIPTIONAL OVERRIDE: A REGULATORY NETWORK 





MicroRNAs (miRNA) are small non-coding regulatory molecules which have been 
implicated in a variety of diseases including cancer. This suggests their usefulness not 
only as early indicators of disease, but as a potential new class of therapeutics. A 
significant hurdle to their clinical application is our inability to predict the response, at 
both genomic and cellular levels, to the repression of miRNA targets. So while the 
mRNA binding sites of the targets of individual miRNAs can be computationally 
identified, a complete understanding of the indirect molecular effects of perturbations in 
miRNA levels remains a major challenge in cancer systems biology. 
Results 
We describe and provide experimental support for a network model to explain the 
unanticipated upregulation of predicted targets of highly expressed microRNAs. We 
found 31 microRNAs upregulated in ovarian cancer samples; many of their miRanda-
mirSVR predicted targets were, as measured by mRNA levels, down-regulated. However, 
over 1500 putative targets were upregulated in our data. We noticed that the expression 
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levels of hundreds of transcriptional repressors were negatively correlated with predicted 
targets of miRNAs in normal tissue. That is, variations across normal ovarian samples 
revealed an inverse relationship between the expression of miRNA targets and 
transcriptional repressors. We show that microRNAs, their mRNA targets, and down-
regulated transcriptional repressor genes can form incoherent feed-forward loops (FFLs) 
which result in the unanticipated upregulation of those targets in cancer (Figure 3.1A). 
We call this FFL motif the Transcriptional Override Model (TOM). 
 
 
Figure 3.1: The transcriptional override model (TOM). This network motif A) typifies 
how the expected down-regulation of target genes by elevated levels of regulating 
miRNAs may be masked or overridden by target gene derepression mediated by miRNA-
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induced downregulation of repressor genes. B) MiRNA-mediated derepression of 
repressor gene ZNF24 (green triangle) overrides the expected downregulatory effects of 




The regulatory effects of changes in miRNA expression levels in vivo are often indirect 
and complex, but may be amenable to systems level modeling. Although TOM was 
developed and validated in the context of ovarian cancer, we believe it may contribute to 
a better understanding of critical genomic interactions in other diseases, and to the use of 
miRNA-based strategies for the treatment of cancer.                                                         
Background 
Human miRNAs regulate gene expression post-transcriptionally by degrading target 
mRNAs and/or blocking their translation  (Bartel 2009). As a consequence, mRNA 
expression changes are expected to be inversely correlated (IC) with changes in levels of 
their targeting miRNAs. Although this expectation has been validated in studies of 
individual miRNAs and specific mRNA targets, the expected inverse relationship is often 
not observed in global transcriptome level studies  (Lim, Lau et al. 2005; (Shahab, 
Matyunina et al. 2011; (Matkovich, Hu et al. 2013). While these unexpected findings 
may, in some instances, be attributable to inaccuracies in miRNA target prediction 
algorithms  (Witkos, Koscianska et al. 2011) or translational repression  (Huntzinger and 
Izaurralde 2011), recent evidence suggests that much of the unexpected regulatory effects 
may be the result of feed-back or feed-forward loops (FFLs) and/or other system level 
complexities
 
 (Tsang, Zhu et al. 2007; (Shahab, Matyunina et al. 2011). Seeking an 
explanation for unexpected interactions in ovarian cancer, we probed our data for the 
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existence of  an FFL consisting of an upregulated miRNA, a down-regulated 
transcriptional repressor, and a mutual gene target. That gene target must satisfy 2 
criteria: 1) it must be a  predicted miRanda-mirSVR target of one or more of the 31 
upregulated miRNAs observed in ovarian cancer, and 2) it must be negatively correlated 
with 1 or more known transcriptional repressors in normal tissue. We show that that FFL 
motif, TOM, accounts for 865 upregulated miRNA targets. 
Results 
To systematically investigate this model, we employed microarray gene expression 
profiling to compare differences in expression levels of mRNAs and miRNAs in ovarian 
surface epithelial cells (OSE) vs. serous papillary epithelial ovarian cancer (EOC) cells 
isolated from patient tissues (Additional file 1) by laser capture microdissection. Gene 
expression profiling identified 5910 significantly differentially expressed genes (mRNAs) 
between OSE and EOC (Additional file 2).  Of these, 2232 (38%) were significantly 
upregulated and 3678 (62%) downregulated in EOC. MiRNA expression profiling 
identified 31 significantly differentially expressed miRNAs between OSE and EOC. All 






Table 3.1: MicroRNAs upregulated in cancer. MiRNA expression profiling identified 




Employing three commonly used miRNA target prediction algorithms (miRanda-mirSVR  
(Betel, Koppal et al. 2010), TargetScan  (Friedman, Farh et al. 2009), SVMicrO  (Liu, 
Yue et al. 2010)), we identified putative mRNA targets of these 31 miRNAs to determine 
if differences in their levels of expression between the OSE and EOC samples were IC, 
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positively correlated (PC) or unchanged (NC). Based on the established molecular 
mechanism of miRNA regulation, levels of miRNAs are expected to be IC with levels of 
their target mRNAs. Contrary to this expectation and consistent with previous findings 
[3], we observed a consistently low percentage (23-31%) of target mRNAs displaying 
expression level changes IC with their regulating miRNAs (Table 3.2). For the remainder 
of this study, we relied on the predictions from miRanda-mirSVR. 
 
 
Table 3.2: Comparison of microRNA target prediction algorithms. This table shows 
the percentage of miRNA target genes displaying changes in expression between OSE 
and EOC as predicted by three popular target prediction algorithms, miRanda/mirSVR, 




The transcriptional override model (TOM) postulates that downregulation of target genes 
induced by elevated levels of regulating miRNAs may be masked (NC) or overridden 
(PC) by increases in expression mediated by the downregulation of repressor genes that 
are themselves targets of upregulated miRNAs (Figure 3.1A). The possibility of such 
feed-forward loops was prompted by the fact that several of the predicted mRNA targets 
of the 31 overexpressed miRNAs encode documented repressors of gene expression (e.g., 
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ZNF24  (Jia, Hasso et al. 2013), YY1  (Bonavida and Baritaki 2011),  SPEN  (Ariyoshi 
and Schwabe 2003), BACH1  (Kitamuro, Takahashi et al. 2003)). MiRNA-mediated 
downregulation of these repressor genes would be expected to result in the derepression 
of their respective target genes and a consequent increase in levels of expression. If these 
derepressed gene targets were also the targets of upregulated miRNAs, the expected 
downregulation of these genes by the miRNAs (IC) could be masked (NC) or overridden 
(PC). For example (Figure 3.1B), one of the predicted targets of ten of the 31 miRNAs 
upregulated in cancer is the well-documented repressor gene ZNF24  (Jia, Hasso et al. 
2013). Consistent with the fact that ZNF24 is targeted by upregulated miRNAs, its 
expression in EOC is significantly reduced. An experimentally validated target of ZNF24 
is VEGFA  (Jia, Hasso et al. 2013). Despite the fact that VEGFA is itself directly targeted 
by 11 upregulated miRNAs (including five of those targeting ZNF24), its level of 
expression is significantly increased (PC) in EOC. These results are consistent with the 
hypothesis that ZNF24-mediated derepression is overriding the expected downregulatory 
effects of the upregulated miRNAs on VEGFA expression. 
Although many of the genes falling within the NC category could be the result of partial 
transcriptional override, they might also simply be the result of no or slight miRNA 
regulatory effects. Since we cannot experimentally distinguish between these two 
possibilities, we will operationally only consider PC differences in expression as being 
inconsistent with the expected IC differences. 
 
To evaluate TOM further, we identified 105 genes that are 1) targets of one or more of 
the 31 upregulated miRNAs, 2) significantly downregulated in our cancer samples and 3) 
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previously characterized as transcriptional repressors  (Ashburner, Ball et al. 2000) 
(Table B.3). The targets of ten (Table 3.3) of these 105 genes have been previously 
identified in the Transcription Factor Binding Site database (TRANSFAC)  (Matys, Kel-
Margoulis et al. 2006).  
 
 
Table 3.3: Ten down-regulated transcriptional repressors. Ten genes characterized as 





This resulted in 843 genes (Additional file 4) predicted to be directly targeted by both the 
ten downregulated repressors and one or more of the 31 upregulated miRNAs. From the 
perspective of miRNA regulation, all 843 of these target genes are expected to be 
downregulated while from the perspective of the downregulated repressor genes all the 
targets are expected to be upregulated. The observed reality lies somewhere between 
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these two expectations (Figure 3.2). TOM predicts that the response of any particular 




Figure 3.2: Highly interconnected network of 31 microRNAs, repressors and their 
mutual targets. Relationships among  31 miRNAs upregulated in cancer (red diamonds), 
ten downregulated repressors that are targets of one or more of the upregulated miRNAs 
(green triangles) and 843 genes that are the gene targets (red and green circles) of both 
the upregulated miRNAs and the downregulated repressor genes. Black lines depict the 
regulatory connection between miRNAs and their target genes; blue lines depict the 
regulatory connection between repressors and target genes. From the perspective of the 
upregulated miRNAs, all target genes should be downregulated (green); from the 
perspective of the downregulated repressors, all target genes should be derepressed 
(upregulated) (red). According to TOM, the response of any particular target gene will be 
determined by the relative strengths of these opposing regulatory controls. 
 
 
The number of miRNAs targeting individual human genes (mRNAs) is known to vary 
from zero to over 100 with an estimated average of 7.1 miRNA targets per gene  (John, 
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Enright et al. 2004). Thus, the relative strength of the regulatory effect of miRNAs on 
target genes might be expected to be a function of the number of miRNAs targeting 
individual genes. To explore this possibility, we grouped the 843 predicted gene targets 
of the 31 upregulated miRNAs and the 10 downregulated repressors into 5 groups based 
upon the number of upregulated miRNAs predicted to target each gene (Figure 3.3A). A 
sixth group was comprised of targets of the ten repressor genes (TRANSFAC) but not 
predicted targets of any of the 31 miRNAs. For each group, we computed the percentage 
of target genes that were upregulated (PC). In addition, for each group we divided the 
target genes into those predicted to be regulated by a single repressor vs. those predicted 






Figure 3.3: Analysis of changes in expression of miRNA regulated repressor genes 
and their predicted target genes is consistent with TOM. The predicted target genes 
(843) of 31 upregulated miRNAs and 10 downregulated repressors were divided into 6 
groups based upon the number of upregulated miRNAs targeting each gene. (The number 
of genes included in each group is shown over the bars.) A) The strength of miRNA 
regulatory control on target genes increases with the number of miRNAs targeting 
individual genes. Bars represent the percentage of upregulated genes. The fact that ~20% 
of genes targeted by even large numbers (16-30) of upregulated miRNAs continue to 
display the unexpected PC is consistent with TOM. The chi-square test for trend is 
(X^2=67.34;p < 0.0001). B) Genes targeted by 2-5 downregulated repressors (red bars) 
override miRNA regulatory effects on co-regulated target genes relative to genes targeted 
by one downregulated repressors (blue bars). The chi-square test for trend for the blue 





The results demonstrate that as the number of upregulated miRNAs targeting individual 
genes increases, the percentage of target genes displaying the unexpected PC change in 
expression decreases. These results are consistent with TOM and indicate that as the 
relative strength of the miRNA regulatory effect increases, the impact of the opposing 
derepression effect mediated by the downregulated repressor genes is diminished. 
However, the fact that 20% of genes targeted by even large numbers (>15) of 
upregulated miRNAs continue to display the unexpected PC indicates that, in some cases, 
the magnitude of derepression is sufficient to completely override miRNA regulation. 
The results presented in Figure 3.3B suggest that genes targeted by multiple repressors 
tend to be associated with a higher percentage of PC genes than those targeted by a single 
repressor. The effect, however, is not as consistent as observed with increasing numbers 
of regulating miRNA likely due to the relatively low number of repressor genes in this 
dataset and the fact that not all repressor genes can be expected to exert the same 
magnitude of regulatory control. 
 
We were next interested to see if the model’s ability to account for trends observed using 
the limited dataset described above might also extend more globally. We divided all 
differentially expressed genes including those that are predicted gene targets of the 31 
upregulated miRNAs (4829) and those that are not (1081), into 6 groups based on the 
number of miRNAs targeting each gene. The results (Figure 3.4A) demonstrate a clear 
inverse relationship between the number of miRNAs targeting genes and the percentage 
of these genes displaying the unexpected PC. Again, however, we found that 20% of 
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genes targeted by even large numbers (>15) of upregulated miRNAs continue to display 
the unexpected PC consistent with the hypothesis that the magnitude of repressor gene 




Figure 3.4: Analysis of global changes in gene expression is consistent with TOM. 
Differentially expressed genes (5910) targeted by upregulated miRNAs were divided into 
6 groups based on the number of miRNAs targeting each gene (The number of genes 
included in each group are presented on top of the bars). A) An inverse relationship exists 
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between the number of upregulated miRNAs targeting genes and the percentage of these 
genes displaying the unexpected PC change in expression. The chi-square test for trend  
is (X^2=311.5; p << .0001), indicating a significant increase in down-regulated targets as 
the number of targeting microRNAs increases. B) The strength of miRNA regulatory 
control is diminished as the number of deregulated repressor genes increase (black bars = 
genes targeted by 0 repressors; blue bars  = genes targeted by 1 repressor; red bars = 
genes targeted by 2-5 repressors; gray bars = genes targeted by 6-30 repressors). A chi-
square test for trend for the miRNAs in this figure (3.4B) is (X^2=444.6; p << .0001), 
indicating a significant increase in down-regulated miRNA targets as the number of 
miRNAs increases. The chi-square test for trend for the transcriptional repressors in this 
figure (3.4B) is (X^2=1904.6; p << .0001), indicating a significant increase in 
upregulated targets as the number of repressors increases. 
 
 
One approach taken by systems biologists to model regulatory relationships in complex 
cellular contexts is to use highly correlated changes in expression patterns among genes 
as evidence of direct and/or indirect interactions  (Allocco, Kohane et al. 2004; 
(Mansson, Tsapogas et al. 2004). In our case, we examined variation in gene expression 
patterns across our OSE samples to identify genes displaying consistent inverse 
correlations (Pearson’s r < -0.8) in expression with changes in expression of the 105 
repressor genes previously characterized as significantly downregulated in EOC and 
regulatory targets of one-or-more of the 31 miRNAs  (see above). Genes displaying an 
inversely correlated pattern of co-expression (n=1205) were operationally classified as 
targets of these repressor genes. Genes not displaying this pattern of expression (n=3624) 
were classified as non-targets of the designated repressor genes. Having established these 
classes, it became possible to distinguish between regulatory interactions fulfilling the 




The results presented in Figure 3.4B again indicate that as the number of upregulated 
miRNAs targeting genes increases, the percentage of the unexpected PC decreases 
significantly (chi-square test for trend X^2=444.6, p<<.0001). The overlap of miRNA 
targets and down-regulated genes,  as seen in the Venn diagram (Figure 3.5B), is also 
highly significant (hypergeometric p < 1E-12). However, consistent with TOM, the 
magnitude of this effect is significantly reduced as the number of downregulated 
repressor genes exerting an opposing effect increases (Figure 3.4A; chi-square test for 
trend X^2=1904.6, p<<.0001). The overlap of repressor targets and upregulated genes 
(Figure 3.5A) is also highly significant (hypergeometric p < 1E-12). Indeed, the results 
indicate that the derepression of target genes mediated by high (6-45) numbers of 
downregulated repressors is sufficient to nearly or completely override the regulatory 
controls of even large numbers (>15) of upregulated miRNAs. 
 
 
Figure 3.5: Upregulated repressor targets and down-regulated miRNA targets show 
significant enrichment  in support of TOM. Venn diagrams show the enrichment of A) 
downregulated targets of miRNAs (Figure 3.4B), which was consistent with our 
transcriptional override model (TOM) using a hypergeometric distribution (p<1E-12, 
population=5910, total down-regulated genes =3678, number of predicted miRNA 
targets=4829, down-regulated miRNA targets=3206); and B) upregulated targets of 
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repressors (Figure 3.4B), which targets are also predicted targets of 1 or more 
upregulated miRNAs, and which we found consistent with TOM using a hypergeometric 
distribution (p < 1E-12, population=4829, total upregulated genes=1623, number of 




Recent studies have clearly established miRNAs as early indicators of disease  (Tijsen, 
Pinto et al. 2012; (Di Leva and Croce 2013) and as a potential new class of therapeutic 
agents  (Shahab, Matyunina et al. 2012; (Gurtan and Sharp 2013). Full appreciation of the 
biological significance of modulations in levels of miRNAs, as well as the future rational 
employment of miRNAs as therapeutic agents, will require an understanding of both the 
direct and indirect molecular consequences of changes in the levels of miRNAs on cell 
function. While the direct gene (mRNA) targets of individual miRNAs can be 
computationally predicted and experimentally validated with varying degrees of accuracy  
(Ritchie, Rasko et al. 2013), reliable predictions of the indirect molecular effects of 
changes in miRNA levels have remained a major challenge in molecular systems biology  
(Gurtan and Sharp 2013; (Vera, Lai et al. 2013). 
 
Testing the model’s ability to globally predict the relative influence of miRNA and 
repressor gene regulatory controls on target gene expression is problematic for two 
reasons: first, a compendium of all human repressor genes and their regulatory targets is 
currently unavailable; second, many regulatory proteins can function as repressors or 
activators depending on cellular context and protein complex association  (Remenyi, 




With that caveat, we present a regulatory network model (TOM) that explains a 
significant component of the unexpected low frequency of IC changes in expression 
levels between mRNAs and their regulating miRNAs. The model postulates that the 
expected down-regulation of target genes induced by elevated levels of regulating 
miRNAs may be masked or “overridden” by increases in transcriptional initiation 
mediated by the down-regulation of repressor genes that are themselves targets of the 
same regulating miRNAs (Figure 3.1A). Depending upon the strength of the 
transcriptional override (i.e., the relative strengths of miRNA and repressor gene 
mediated derepression), TOM suggests that increases in miRNA levels may display no 
effect (NC) or be positively correlated (PC) with changes in levels of their targeted 
mRNAs. We show that the model successfully accounts for a majority of the unexpected 
relationships observed between changes in miRNA levels and levels of their targeted 
mRNAs measured in the same cohort of cancer epithelial cells isolated from a series of 
ovarian cancer patients (Additional file B.1).  
 
While we have evaluated TOM within the context of its ability to account for global 
patterns of changes in gene expression, the model also provides a framework for 
explaining specific interactions between miRNAs and target genes (e.g., Figure 3.1B). 
Thus, TOM may be of use in not only establishing the likely consequence of exogenous 
expression of miRNAs on specific target genes, but in predicting likely indirect global 




It is now widely acknowledged that the complexity of molecular interactions taking place 
on the cellular level can significantly obscure the expected consequences of molecular 
processes characterized in vitro,  (Hornberg, Bruggeman et al. 2006; (Vidal, Cusick et al. 
2011). Our findings indicate that the direct and indirect regulatory effects of changes in 
miRNA expression levels in vivo are interactive and complex but amenable to systems 
level modeling. We have shown that TOM can account for a major component of the 
unexpected consequences of changes in miRNA expression levels on their target 
mRNAs. Although the model has been developed and evaluated within the context of 
ovarian cancer, we believe it may be applicable in other biological contexts as well 
including the potential use in the rational design of miRNA-based strategies for the 
treatment of cancer and other diseases.  
Methods 
All tissues were collected according to previously published procedures (Bowen, Walker 
et al. 2009) following approved Institutional Review Board protocols from Northside 
Hospital (Atlanta) and Georgia Institute of Technology. Informed consent was obtained 
from all subjects. The histopathology for all cancer patients was serous papillary 
adenocarcinoma of the ovary and for the control patients the ovaries were considered 
within normal limits. 
 
mRNA microarray data analysis 
Ten OSE (normal) and ten EOC (cancer) samples were analyzed for mRNA expression 
using the Affymetrix Gene Chip Operating System (GCOS HG-U133 Plus 2.0). CEL 
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files generated by GCOS were converted to expression values using GCRMA 
normalization on the arrayanalysis.org (Eijssen, Jaillard et al. 2013) website, whose 
output also included quality control metrics, principal components analysis (PCA) and 
cluster dendrograms. Present/absent calls were generated from the MAS 5.0 statistical 
algorithm as implemented in Affymetrix Expression Console. Probe sets with >60% 
present calls in either of the two groups (OSE and EOC) were selected for further 
analysis. After log2 transformation, signal values of those probe sets were submitted to 
Statistical Analysis of Microarrays (SAM) for multiple testing correction where a 5.5% 
FDR was applied resulting in 7462 probe sets representing 5910 differentially expressed 
genes (DEGs). Annotations for probe sets were obtained from Affymetrix (Affymetrix). 
The processed and raw data files for the samples used in this study have been deposited 
in the Gene Expression Omnibus (GSE52037 with superseries GSE52460). 
 
microRNA microarray data analysis 
Expression profiles for miRNAs from three OSE and three EOC samples were generated 
by Asuragen (Austin, TX) using Ambion miRChip technology (Life Technologies). Two 
sets of CEL files, created from 6 biological replicates and two sets of technical replicates 
were normalized using MAS 5.0 to expression signals, giving 6 values per probe/gene. 
Probe sets labeled as human (those having an “hsa-“ prefix), known to be conserved to 
mouse (mmu), and with at least 65% present calls (calculated by Asuragen) in either of 
the two groups (OSE and EOC) were selected for further filtering. Thirty-one 
differentially expressed miRNAs (fc > 6, p-value < .03) were selected. The repressive 
potential of all 31 miRNAs was validated by noting that > 65% of the predicted DEG 
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targets of each upregulated miRNA were actually down-regulated, while only 44% of 
DEGs not predicted to be targets of any upregulated miRNA were downregulated. Mean 
repression over all 31 miRNAs was 71%. The processed and raw data files for the 
samples used in this study have been deposited in the Gene Expression Omnibus 
(GSE52459 with superseries GSE52460). 
 
microRNA target prediction 
The miRNA target prediction file based on mirSVR was downloaded from miRNA.org 
(August 2010 release). The mirSVR score refers to targets of miRNAs with scores 
obtained from their support vector regression algorithm. To reduce the occurrence of 
false positives, only predicted targets with a mirSVR score less than -.2 were considered. 
The miRNA target predictions based on TargetScan and SVMicrO were downloaded 
from www.targetscan.org (retrieved 8/2010) and 
www.compgenomics.utsa.edu/Result/Human/hsa_human (retrieved 9/2010), respectively. 
 
Transcriptional repressor selection 
Members of the Gene Ontology categories GO:0045892, GO:0000122, GO:0010944, 
GO:0032088 and GO:0008156, relating to the negative-regulation-of-transcription or its 
child terms, were downloaded from the European Bioinformatics Institute (EBI) and 
parsed using UNIX scripts. In that download, we found 439 potential repressor genes. Of 
those, 109 genes were significantly down-regulated according to our microarray analysis 
and 105 of these genes were also predicted targets of one or more of the 31 upregulated 
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miRNAs (v.s.). These 105 transcriptional repressor genes formed the basis for miRNA 
target derepression in our model. 
 
Transcriptional repressor target prediction and experimental validation 
To obtain predicted and/or experimentally validated transcription factor binding site data, 
we downloaded the TRANSFAC data file c3.tft.v3.1.symbols.gmt from GSEA (Gene 
Set Enrichment Analysis website - http://www.broadinstitute.org/gsea/downloads.jsp). 
Data files were parsed with UNIX scripts, which extracted pairs of genes consisting of 
one repressor and one or more binding partners. All repressor-partner pairs under 
consideration had to be DEGs and predicted targets of at least one of the 31 upregulated 
miRNAs, and all transcriptional repressors were down-regulated in cancer. Further, all 
repressor-partner pairs were required to show a correlation coefficient of r < -.8 across all 
normal samples.  
 
Correlation coefficient calculation 
For the global analysis of relationships among all 105 transcriptional repressors and their 
binding partners, Pearson’s correlation coefficient (PCC) was calculated across all ten 
OSE (normal) samples between all transcriptional repressors and predicted miRNA 
targets. Specifically, we used the Mathematica (Wolfram Research 2010) correlation[] 
function (n=10; r < -.8) for a directional significance of (p < .0027). Fold-change from 
normal to cancer in these genes ranged from -625 to 121. 
 
Availability of supporting data 
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The processed and raw data files for the samples used in the mRNA and miRNA 
expression studies have been deposited in the Gene Expression Omnibus (GSE52037 and 





EVIDENCE OF SIGNIFICANT CHANGES IN GENE NETWORK 
INTERACTIONS IN OVARIAN CANCER 
Introduction 
It has become increasingly clear in recent years that the molecular basis of cancer and 
other complex human diseases is not merely attributable to structural and/or regulatory 
mutations in one or a few genes but additionally to disruptions in networks of regulatory 
interactions existing among these and other components of the genome (Ideker, Galitski 
et al. 2001; (Vidal, Cusick et al. 2011; (Wu, Zhu et al. 2012; (Ying, Lv et al. 2013).  
Although an experimental determination of the myriad of potential genetic interactions 
that characterize human cells is only beginning to be established experimentally e.g.,  
(Vidal, Cusick et al. 2011), a number of computational approaches have recently been 
developed that can directly or indirectly infer interactive network relationships among 
genes in normal and cancer cells (Laubenbacher and Stigler 2004; (Schafer and Strimmer 
2005; (Kar, Gursoy et al. 2009; (Barabasi, Gulbahce et al. 2011). The standard input for 
gene regulatory network algorithms is gene expression (RNA-seq and/or microarray) 
datasets. Interactions (edges) between genes (nodes) can be inferred in an unsupervised 
fashion based upon consistent and highly correlated changes (positive or negative) in the 
expression patterns that exist among genes in multiple biological samples (Roth, Hevezi 
et al. 2006; (Amar, Safer et al. 2013). In this study, we employ an unsupervised (Pearson 
correlation) approach to estimate overall gene network relationships between precursor 
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(control) ovarian surface epithelial cells (OSE) and serous papillary ovarian cancer 
epithelial cells (CEPI) isolated from human patient samples by laser capture 
microdissection (LCM) and analyzed by gene expression microarray (Affymetrix, U133 
Plus 2) as previously described (Bowen, Walker et al. 2009). The initial results indicate 
that ovarian cancers display a significant overall reduction in correlated gene interactions 
relative to normal precursor cells. Consistent with this finding, we further show that 
biological processes identified by gene ontology (GO) analyses to be significantly over-
represented among differentially expressed genes were substantially different from those 
overrepresented among genes involved in qualitatively disrupted network interactions. 
Although many of the genes associated with qualitatively disrupted network interactions 
have been previously implicated in ovarian and other cancers, others may represent 
potential new targets for therapeutic intervention.  
 
Results 
Ovarian cancer is associated with a significant reduction in gene network 
interactions relative to normal precursor cells. 
We employed microarray gene expression analysis to compare differences in gene 
expression levels between precursor ovarian surface epithelial (OSE) cells and ovarian 
cancer epithelial cells (CEPI) isolated from patient tissue samples by laser capture 
microdissection (LCM). Gene expression profiling identified 5,070 significantly 
differentially expressed genes (mRNAs) between the OSE and CEPI samples (Table 
C.1). Of these, 1,436 (28%) were significantly up-regulated and 3,634 (72%) 
significantly down-regulated in the cancer samples relative to normal controls. 
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Baseline relationships (Pearson correlations) between significantly differentiated genes in 
the control samples (OSE) were established by comparing the expression levels of 12.8 
million pairs of genes (5,070 X 5,069 / 2) across 10 normal patient samples and selecting 
gene pairs displaying highly correlated (positive or negative) expression levels across 
samples. This resulted in a total of 682,391 (< 5% of all possible pairings) significantly 
correlated (positive and negative) pairs of differentially expressed genes (r > 0.85 ; p < 
.0018;  Note: we determined that (r) < 0.85 can occur purely by chance - Figure 4.1). 
 
 
Figure 4.1: Comparison of normal, cancer and random network connectivity. Each 
point on the three lines of this graph represents the size of the largest connected sub-
network as a percentage of the total number of correlated genes, across 10 samples, at 
that r value (.70 < r < .99). The graph compares connectedness among correlated DE 
genes using normal (dark blue line), cancer (green line) and 500 randomly generated 
(yellow) expression values across different values of r. This comparison shows that even 
random expression values can generate apparently highly correlated networks at r < .85. 





Of these 682,391 correlated gene pairs, 568,083 were positively correlated with one 
another while 114,505 were negatively correlated. Conducting the same analysis across 
the 10 cancer (CEPI) samples resulted in less than 193,288 highly correlated (positive 
and negative) gene pairs (r > 0.85, p<0.0018) implying a substantial net loss in regulatory 
control in the ovarian cancer samples. Of the nearly 193,000 highly correlated gene pairs 
in cancer, 164,295 were positively correlated with one another while 29,005 were 
negatively correlated. Thus, only ≈35,000 pairs of genes (~5% of 682,391) were found to 
maintain the same patterns of expression between one another in the normal and cancer 
samples. These findings are consistent with previous experimental evidence indicating 
that cancer cells are generally associated with a significant loss in regulatory control 
relative to normal precursor cells; e.g.,  (Ford and Pardee 1999; (Zhao, Sun et al. 2012; 
(Cordero, Sole et al. 2014).  
 
More than 45,000 gene pair relationships identified in normal samples qualitatively 
change in cancer samples.  
While the above results indicate that a majority of gene pair interactions are disrupted in 
cancer, the findings are difficult to functionally interpret because relatively small 
quantitative changes in the expression levels of gene pairs between normal and cancer 
samples can significantly affect the gain or loss of pair-wise correlations, many of which 
may not be of biological significance. For this reason, we limited our subsequent analyses 
to gene pairs displaying qualitative reversals in interactive relationships (positive to 
negative or negative to positive) between the normal and cancer samples. Such 
qualitative reversals in regulatory controls have been previously shown to be associated 
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with functionally significant changes in cancer; e.g.,  (Oyake, Itoh et al. 1996; (Remenyi, 
Scholer et al. 2004; (Gordon, Akopyan et al. 2006; (Thompson, Xu et al. 2009). Gene 
pairs displaying the same qualitative patterns in normal and cancer samples, i.e., gene 
pairs with expression patterns that are consistently positively or negatively correlated in 
both normal and cancer samples, are classified as “consistent”. Conversely, gene pairs 
with expression patterns that display qualitatively different relationships in the normal 
and cancer samples, i.e., gene pairs that display positively correlated relationships in 
normal tissues but negatively correlated relationships in cancer tissues and vice versa, are 
classified as “inconsistent”. Of the 568,083 positively correlated gene pairs detected in 
the normal samples, 534,011 (94%) were found to maintain this same qualitative 
relationship in the cancer samples (“consistent”).  Similarly, of the 114,505 negatively 
correlated gene pairs detected in normal samples, 103,277 (90%) were found to maintain 
this qualitative relationship in cancer (consistent). Thus, a total of only 45,300 (6.6%) 
gene pairs displayed a reversal in gene pair relationships in cancer (“inconsistent”).  
 
Genes associated with inconsistent gene pair relationships in cancer are significantly 
enriched for cell cycle and cell death related functions. 
To determine if genes associated with inconsistent network relationships in our cancer 
samples were enriched for specific biological functions, we selected from the 45,300 
pairs of genes involved in at least one inconsistent interaction, 350 genes associated with 
the greatest number of inconsistent interactions (Table C.2) and submitted them to 
DAVID (Database for Annotation, Visualization and Integrated Discovery) (Huang da, 
Sherman et al. 2009) for pathway enrichment analysis . The results (Table 4.1) identified 
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cell cycle related functions (red) as the most significantly enriched biological processes in 
this group of genes followed closely by functions associated with programmed cell death 
(green) (Figure 4.1a,b).  
 
 
Table 4.1: Gene ontology enrichment of the top 350 inconsistent genes. The 350 
genes involved in the greatest number of  inconsistent pair-wise interactions across all 
highly correlated genes were analyzed for biological process enrichment using DAVID. 
M Phase (p < 9.38E-10) and other biological processes related to cell cycle (green) were 
found to be the most significant processes. Apoptosis and 11 other related processes 









Figure 4.2: Networks of enriched genes. Two networks showing consistent (blue) and 
inconsistent (yellow) interactions (edges) between DE genes (nodes) as those interactions 
appear in cancer. Red nodes represent genes upregulated in cancer, while green nodes are 
down-regulated. Genes were selected based on their membership in either (A) cell cycle 
(GO:0007049) or (B) regulation of programmed cell death (GO:0045076). The (A) 
network shows 598 pairs of cell cycle genes which were highly correlated (r > 0.85) 
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across 10 normal samples, while the (B) network shows 924 pairs of highly correlated 
genes related to programmed cell death. 
 
 
Genes associated with qualitatively disrupted network interactions in ovarian 
cancer identify a potential new class of candidates for targeted gene therapy. 
A current molecular standard used to identify functionally significant genetic changes in 
cancer is changes in gene expression (Welsh, Sapinoso et al. 2001). To determine the 
extent to which processes identified as significantly overrepresented among genes 
involved in disrupted network interactions (see above) were similar or different from 
processes overrepresented in genes most significantly differentially expressed, we 
selected the 350 most significantly differentially expressed genes between the normal and 
cancer samples (Table C.3) and subjected them to the gene ontology analysis. As shown 
in Table 4.2, the biological processes most significantly overrepresented among 
differentially expressed genes was substantially different from those most significantly 





Table 4.2: Gene ontology enrichment of the top 350 differentially expressed genes. 
The 350 genes with the greatest fold change from normal to cancer (FC < -9.21 and 9.27 
< FC) were analyzed for biological process enrichment using DAVID. Cell adhesion (p < 




Indeed, of the 350 genes most significantly differentially expressed between our normal 
and cancer samples, only 22 overlapped with the 350 genes involved in the most 








Figure 4.3: Venn diagram showing overlap between differentially expressed vs. 
inconsistent genes. The light gray circle on the left represents 350 genes which were 
involved in the greatest number of inconsistent pairs in normal samples, while the circle 
on the right represents 350 most differentially expressed genes. Only 22 genes are 




These results suggest that the identification and characterization of genes involved in 
disrupted gene network interactions in ovarian and perhaps other cancers may constitute 
an important source of functionally significant information unavailable through gene 
expression analyses alone. 
 
Many of the genes associated with inconsistent interactions have been previously 
implicated in cancer. 
We found that many of the genes involved in inconsistent interactions in ovarian cancer 




Table 4.3: Inconsistent genes implicated in cancer. 
This table shows that of 34 genes involved in large numbers of inconsistent pairings, 29 
have been previously implicated in ovarian cancer and 5 others have been reported in 
other cancers. Column 1 indicates whether the gene is a known drug target, according to 
the CancerResource (Ahmed, Meinel et al. 2011). Columns 2-6 show the gene symbol, 









Y AURKA 16.9 51 ovarian 
 (Wrzeszczynski, Varadan et 
al. 2011) 
Y BARD1 2.1 103 ovarian  (Deng 2006) 
Y CCNA2 2.9 221 ovarian  (Bowen, Walker et al. 2009) 
Y CCNB1 5.7 210 ovarian  (Bast 2011) 
Y CDK1 9.6 79 ovarian  (See, Kavanagh et al. 2003) 
Y CHEK1 4.0 187 ovarian 
 (Bertoni, Codegoni et al. 
1999) 
Y COL1A2 2.8 612 ovarian  (Karlan, Dering et al. 2014) 
N COL5A2 2.1 419 ovarian 
 (Helleman, Jansen et al. 
2006) 
N DNA2 1.7 209 ovarian  (Miles, Seiler et al. 2012) 
N EZR -41.8 398 ovarian Poersch ‘14 
N FANCD2 7.0 209 ovarian 
 (Lewis, Flanagan et al. 
2005) 
N FEN1 2.4 56 ovarian 
 (Abdel-Fatah, Russell et al. 
2014) 
N FGFR1OP 2.2 322 ovarian  (Huang, Chen et al. 2012) 
N HMGB3 3.7 430 ovarian 
 (Helleman, Jansen et al. 
2006) 
Y HTATIP2 2.1 128 ovarian 
 (Kumtepe, Halici et al. 
2013) 
Y KIAA0101 12.7 118 ovarian 
 (Emmanuel, Gava et al. 
2011) 
Y MAD2L1 2.8 263 ovarian  (Park, Jeong et al. 2013) 
N MDC1 1.6 54 ovarian  (Deng 2006) 
Y MECOM 18.6 20 ovarian 
 (Ramakrishna, Williams et 
al. 2010) 
Y PRC1 3.7 56 ovarian 
 (Ehrlichova, Mohelnikova-
Duchonova et al. 2013) 
N PTPRM 4.2 506 ovarian  (Gyorffy, Dietel et al. 2008) 
Y RAD51AP1 8.1 88 ovarian  (Miles, Seiler et al. 2012) 
N RAD52 1.8 169 ovarian  (Auranen, Song et al. 2005) 
N RMI1 1.7 495 ovarian 
 (Moolthiya and Yuenyao 
2009) 
Y STMN1 1.6 177 ovarian  (Ying, Su et al. 2013) 
Table 4.3 (continued) 
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N TIMELESS 3.0 61 ovarian 
 (Tokunaga, Takebayashi et 
al. 2008) 
Y TOPBP1 1.8 116 ovarian 
 (Karppinen, Erkko et al. 
2006) 
Y WWOX -2.0 189 ovarian  (Gourley, Paige et al. 2005) 
Y XPR1 2.3 645 ovarian 
 (Nikolova, Doganov et al. 
2009) 
N CSNK2A1 1.8 84 pancreatic 
 (Giroux, Iovanna et al. 
2006) 
Y HELLS 2.2 576 NSCLC  (Yano, Ouchida et al. 2004) 
N TET1 1.6 574 prostate  (Hsu, Peng et al. 2012) 
Y VRK1 1.9 650 breast 
 (Valbuena, Castro-Obregon 
et al. 2011) 
N ZWILCH 1.6 294 breast 





For example, CHEK1 (checkpoint kinase 1), a regulator of DNA damage-induced cell 
cycle (G2/M) arrest (Ouyang, Yao et al. 2009) and associated with 187 inconsistent 
interactions in our cancer samples (Table C.2), has been previously identified as regulator 
of tumor suppressor functions and as a potential target for cancer gene therapy (Helleday, 
Petermann et al. 2008; (Khanna, Kauko et al. 2013). MECOM (MDS1 And EVI1 
Complex Locus) has been shown to be commonly amplified in ovarian cancer and has 
also been identified as a potential target for cancer gene therapy (Ramakrishna, Williams 
et al. 2010; (Cancer Genome Atlas Research 2011). 
A number of other genes involved in inconsistent interactions in our ovarian cancer 
samples, although not yet implicated in ovarian cancer, have been identified as important 
contributors to other types of cancer. For example, the gene involved in the greatest 
number of inconsistent interaction in ovarian cancer (650), VRK1 (vaccinia-related 
kinase-1), has been previously associated with cell cycle and cell death functions 
(Valbuena, Castro-Obregon et al. 2011) and has recently been implicated in breast cancer 
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(Molitor and Traktman 2013). Likewise, the TET1 (ten-eleven translocation 1 gene) 
gene, which we found to be involved in 574 inconsistent interactions in OC, has been 
recently identified as a tumor suppressor gene associated with prostate cancer (Hsu, Peng 
et al. 2012). Another tumor suppressor gene, HELLS found to be involved in 576 
inconsistent interactions in OC has been previously associated with epigenetic 
deregulation leading to lung cancer onset and/or progression (Yano, Ouchida et al. 2004). 
A number of the genes involved in inconsistent interactions in our ovarian cancer 
samples, although not yet explicitly implicated in any human cancer, are nevertheless 
known to be involved in important cellular functions and thus may represent a currently 
under appreciated class of cancer associated genes. For example, XPR1 (xenotropic and 
polytropic retrovirus receptor-1) is an atypical trans-membrane signaling receptor 
associated with G-protein coupled receptor activity (Vaughan, Mendoza et al. 2012). 
Although XPR1 is currently functionally recognized only as a receptor for xenotropic and 
polytropic retroviruses this is clearly not its primary cellular function. The fact that XPRI 
is associated with 645 inconsistent interactions in our ovarian cancer samples suggests 




Modern high-throughput sequencing and gene expression technologies are providing 
unprecedented insights into the molecular genetic processes disrupted in cancer, e.g.,  
(Cancer Genome Atlas Research 2011; (Yates and Campbell 2012) and have led to the 
possibility of a personalized, targeted gene approach to cancer therapy (Dachs, 
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Dougherty et al. 1997). However, since not all variants detected by high-throughput 
technologies may be of functional significance, high-throughput sequencing and gene 
expression data must be coupled with the capability to distinguish functionally important 
or “driver” variants from “passenger” variants of little on no relevance. A major barrier 
to the attainment of this goal is the fact that the eukaryotic genome is a highly integrated 
network; e.g.,  (Barabasi and Oltvai 2004). As a consequence, the biological significance 
of a genetic variant in any particular cancer can reasonably be expected to depend, to a 
greater or lesser extent, upon the functional status of other genes with which it interacts. 
The growing realization of the potential importance of gene interactions in a variety of 
diseases; e.g.,  (Barabasi 2007), including cancer, e.g.,  (Laufer, Fischer et al. 2013; (Hill, 
Matyunina et al. 2014; (Kim, Li et al. 2014) is spurring the development of new and 
relevant experimental and computational tools to identify and evaluate the significance of 
changes in gene network relationships in eukaryotic cells; e.g.,  (Djebbari and 
Quackenbush 2008; (Laubenbacher and Jarrah 2009; (Nagaraj and Reverter 2011; 
(Moreau and Tranchevent 2012). Interactions between genes are typically 
computationally inferred in an unsupervised fashion based upon consistent and highly 
correlated changes (positive or negative) in the expression patterns between genes in 
multiple biological samples; e.g.,  (Soneson, Lilljebjorn et al. 2010; (Madhamshettiwar, 
Maetschke et al. 2012; (Stephens, Tarpey et al. 2012). Although, such unsupervised 
approaches typically infer network relationships exclusively from minimally processed 
gene expression data, more supervised methods (e.g., Bayesian (Kang, Zheng et al. 
2011),  partial correlation (Madhamshettiwar, Maetschke et al. 2012) etc.) incorporate 
additional supplementary information, such as current understanding of specific gene 
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regulatory relationships. While supervised methods can have advantages when inferring 
network changes in previously established, well-defined pathways, they can be less 
effective in detecting previously unrecognized interactions and/or in detecting important 
yet previously undefined system-wide changes in network structure. For example, 
supervised algorithms using Bayesian networks typically operate on directed acyclic 
graphs (DAG), that do not include loops from the network. Such procedures can result in 
the loss of biologically relevant data since feedback loops are widely recognized as 
biologically significant eukaryotic cells in general, e.g., (Pomerening 2009) and 
particularly in cancer; e.g., (Harris and Levine 2005; (Su, Liu et al. 2014) . 
In this study, we were interested in exploring the possible significance of changes in gene 
interactions in ovarian cancer by comparing differences in correlated patterns of gene 
expression between precursor ovarian surface epithelial (OSE) cells and ovarian cancer 
epithelial cells (CEPI) isolated from 10 normal and 10 cancer patient samples.  Using an 
unsupervised computational approach (Pearson correlation), we found evidence of a 
significant overall loss in gene-gene interactions in our cancer samples. These results are 
consistent with earlier computational and experimental studies suggesting that cancers are 
generally associated with an overall reduction in regulatory control  (Ford and Pardee 
1999; (Zhao, Sun et al. 2012; (Cordero, Sole et al. 2014).  
In an effort to associate the most significant changes in gene pair interactions with 
specific biological functions, we developed a novel approach to identify gene pair 
interactions that qualitatively change in cancer samples. We found that genes involved in 
qualitative changes in gene pair interactions in our cancer samples were most 
significantly associated with biological processes involved in cell cycle regulation and 
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cell death.  Interestingly, the genes identified as most frequently involved in these 
processes were not among the genes most significantly differentially expressed between 
our cancer and control samples. These results suggest that the identification of genes 
involved in disrupted network interactions in cancer may represent a clinically significant 
class of genes that may go undetected in standard mutational and gene expression 
analyses.  
The long-term hope of converting cancer from a lethal to a manageable chronic disease 
rests not only upon the availability of technologies to accurately detect structural and 
expression genetic variants associated with individual tumors but analytical methods that 
can reliably identify those variants that are causally responsible for the cancer phenotype 
in individual patients.  Our results indicate that the simple identification of genes mutated 
and/or differentially expressed in cancer tissues may not be sufficient to identify all genes 
of functional significance. The development and implementation of novel methods to 
identify genes involved in disrupted network interactions in cancer promises to provide 
important new insight into the processes underlying cancer and the potential 








Gene expression profile 
We downloaded gene expression data from the Gene Expression Omnibus (GEO 
accession:  GSE52037). The expression profiles were performed on ten normal ovarian 
surface epithelial (OCE) and ten serous papillary cancer epithelial (CEPI) samples (see  
(Hill, Matyunina et al. 2014) for details) and analyzed for changes in mRNA expression 
using the Affymetrix Gene Chip Operating System (GCOS HG-U133 Plus 2.0). CEL 
files generated by GCOS were converted to expression values using GCRMA 
normalization on the arrayanalysis.org [33] website, whose output also included quality 
control metrics and cluster dendrograms. Present/absent calls were generated from the 
MAS 5.0 statistical algorithm as implemented in Affymetrix Expression Console. Probe 
sets with >60% present calls in either of the two groups (OSE and CEPI) were selected 
for further analysis. After log2 transformation, the signal values of those probe sets were 
submitted to Statistical Analysis of Microarrays (SAM) for multiple testing correction 
where a 5.5% FDR was applied resulting in 7461 probe sets representing 5910 unique 
genes; annotations for probe sets were obtained from Affymetrix [34]. Genes were 
further filtered for absolute fold change > 1.5 between normal and cancer samples, 
resulting in 5144 differentially expressed (DE) genes. Further analysis of DE genes 
which were detected by exactly two probe sets revealed that ~2.5% of the probe sets 
reported contradictory results for a given gene; genes with contradictory probe sets were 





Pearson correlation between DE genes was calculated using the Mathematica (Wolfram 
Research 2010) correlation function. Since it is possible that the gene to gene correlation 
might be random, a significance test was conducted using expression signals from normal 
samples. For each Affymetrix probe set, expression signals from the 10 normal samples 
were shuffled among those 10 samples. That is, expression values were randomly 
reassigned to different samples, thus preserving the mean and standard deviation. By 
graphing the size of the largest connected subgraph for different values of r ranging from 
0.70 to 0.99 [Supplemental Figure 1], it was found that networks of random signals can 
appear to be connected for values of  r < 0.85. To minimize false positives, the absolute 
value of  r was limited to values > 0.85. Baseline relationships between pairs of DE genes 
were established by correlating the expression of 12.8 million pairs of probes across 10 
normal samples, and selecting pairs satisfying (r > 0.85 ; df = 8; p < 0.0018). This 
resulted in a total of 682391 highly correlated gene pairs. Random expression values can 
generate apparently highly correlated networks at r < .85 (Figure 4.1). Based on this 
analysis, r was set to .85 to minimize the possibility of unjustifiable correlations. 
 
Gene enrichment 
Lists of 350 inconsistent and 350 highly DE genes were subjected to genome ontology 
enrichment analysis by using the Database for Annotation, Visualization and Integrated 
Discovery (DAVID) (Huang da, Sherman et al. 2009). The lists were analyzed using  





Gene ontology selection 
Cell cycle genes (n=577) (GO:0007049) and genes involved in the Regulation of 
Programmed Cell Death (n=892) (GO:0043067) were downloaded from QuickGO 
(Binns, Dimmer et al. 2009) after filtering for Taxon (human:9606), Evidence (Manual 
all), GO Identifier (GO: 0007049 or GO: 0043067 and their descendants), and Aspect 
(Biological Process). These genes formed the basis for Figures 1a and 1b, which were 
built using Cytoscape (Shannon, Markiel et al. 2003). 
 
Graph construction and visualization 
Cytoscape was used to visualize the correlation networks consisting of DE genes 
downloaded from QuickGO, by using a Prefuse Force Directed layout. The top 6 most 
highly correlated neighbors for each gene were connected to form a graph. Genes with 







Throughout these studies, we were interested in investigating and explaining the possible 
causes of aberrant gene expression in ovarian cancer. The studies include analyses of 
interactions among genes, transcription factors and microRNAs, and explore how their 
dysregulation relates to cancer. Above all, our findings lead us to believe that it is 
difficult, if not impossible, to understand the breakdown of biological systems by simply 
measuring changes in expression of single genes or individual microRNAs. Instead, a 
deeper appreciation of the operation of a biological system as a network of 
interdependent elements requires some approximation, however crude, of the system 
itself, which can only be hinted at by lists of isolated, differentially expressed genes. And, 
while a detailed mechanistic model of even a single human cell is as yet intractable, some 
biologically meaningful approximation of that mechanism is needed to improve our 
current understanding. This dissertation basically addresses three questions: 1) to what 
extent do the predicted targets of miRNAs that differ by a single nucleotide in their seed 
region overlap; 2) what is the net effect on the expression of genes that are both predicted 
targets of upregulated microRNAs and negatively correlated targets of down-regulated 
transcriptional repressors; 3) what can we learn from inconsistent genes, that is, genes 
which change their relationship to other genes as the tissue they are expressed in becomes 
cancerous. 
In the first study (Chapter 2), we showed how a single mutation in the 7-mer seed region 
of a microRNA can potentially affect the expression of hundreds of genes and therefore 
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influence a large number of biological processes. We found that while miRNAs with 
identical seeds share 88% of their mirSVR predicted targets, a single nt change reduced 
that overlap to about 18%. Subsequent mutations resulted in no additional loss of overlap. 
Surprisingly, even miRNAs whose seeds had no positions in common share about 16% of 
their targets. Due to the capacity of the 3’UTR of a targeted mRNA to accommodate a 
large number of miRNA binding sites, the mapping of seed sequences to functions that 
are mediated by their targeted genes, appears random. Random, in the sense that 
transcripts mediated by a miRNA with a novel seed are uninformed by a knowledge of 
transcripts mediated by other miRNAs with similar seeds. The high number of mutual 
targets among elements of individual miRNA families (miRNAs sharing identical seeds), 
accomplished both  through seed equivalence and by having multiple binding sites on 
their targets, provides robustness (Siciliano, Garzilli et al. 2013) and process stability, but 
induces complexity (Lee, Risom et al. 2007; (Peter 2010). This may confound naive 
interpretations of miRNA transfection experiments; the high number of  targets mediated 
by multiple miRNAs leads to complex interactions, including feedback loops (Lee, 
Risom et al. 2007) which are difficult to model or to tease apart experimentally (Tsang, 
Zhu et al. 2007). Thus, attribution of downstream mRNA expression variation, let alone 
specific biological functions, to a particular miRNA becomes computationally if not 
experimentally intractable. This underscores our claim that cancer must be approached as 
a system. 
The idea that miRNA target determination is binding site dependent (rather than seed 
dependent) suggests a decoupling of miRNA seed structure from biological function; 
seeds are codes (Barbieri 2008). This observation questions assumptions of a causal link 
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between seed sequence and function, and instead proposes that seeds are biologically 
agnostic. This leads us to conclude that while miRNAs target mRNAs directly, they 
mediate biological functions indirectly. And while we do not deny that many miRNAs 
can be associated a posteriori with specific biological functions (Nam, Li et al. 2009; 
(Backes, Meese et al. 2010), we believe that that relationship is adventitious, and that the 
miRNAs only persist in regulating sets of mRNAs involved in evolutionarily beneficial 
biological functions. 
 
In the second study (Chapter 3), we presented TOM, the transcriptional override model, 
in which we showed that even a simple feed-forward loop (FFL) motif can reveal 
unpredicted yet explanatory interactions among three genetic elements. Using TOM, we 
accounted for the indirect and unexpected upregulation of hundreds of predicted 
microRNA targets in ovarian cancer which might naively be anticipated to be down-
regulated. We further showed that changes in expression among thousands of microRNA 
targets depend on a balance between the repressive effects of dozens of upregulated 
microRNAs, and the derepressive effects of over 100 down-regulated transcriptional 
repressors. The impact of these findings should not be underestimated; the possibility of 
microRNA mediated therapeutics will depend on an accurate assessment of both direct 
and indirect consequences of exogenous microRNA transfection. 
The final study (Chapter 4) introduces the concept of inconsistent genes, which are 
derived from gene pairs which are highly correlated in normal tissue, but become 
dysregulated in diseased tissue. Surprisingly, most pairs of genes retain the same 
relationship in cancer as they did in normal samples; these consistent gene pairs 
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accounted for 94% of all significant relationships. And while inconsistent genes 
accounted for only about 6% of all correlated genes, we found many had previously been 
implicated in cancer and, even more interestingly, were involved in cell cycle and 
regulation of programmed cell death. We also found that there were fewer highly 
correlated genes pairs in cancer than in normal tissue, which we speculated might be 
accounted for by a loss of control in cancer, and/or the existence of multiple populations 
in the tumor. Further, we found that negatively correlated gene pairs in normal samples 
were more likely to become dysregulated (inconsistent) in cancer, and that those 
negatively correlated pairs were significantly more likely to be upregulated. 
All three studies, while taking different approaches, emphasize the need to approach gene 
dysregulation in cancer from a systems perspective which requires the application of 






SUPPLEMENTARY DATA FOR CHAPTER 2 
 
 
Table A.1: Fold-change for DE genes after MIR429 transfection. Sheet1: All 5229 
differentially expressed genes between negative controls and transfected HEY cells. 
Sheet2: 874 predicted and down-regulated genes after transfection. 
Please see table on our website: 
http://www.mcdonaldlab.biology.gatech.edu/dissertations/hill.htm 
 
Table A.2: Fold-change for DE genes after MIR200b transfection. Sheet1: All 6690 
differentially expressed genes between negative controls and transfected HEY cells. 
Sheet2: 1006 predicted and down-regulated genes after transfection. 
Please see table on our website: 
http://www.mcdonaldlab.biology.gatech.edu/dissertations/hill.htm 
 
Table A.3: Fold-change for DE genes after MIR141 transfection. Sheet1: All 7269 
differentially expressed genes between negative controls and transfected HEY cells. 
Sheet2: 724 predicted and down-regulated genes after transfection. 
Please see table on our website: 
http://www.mcdonaldlab.biology.gatech.edu/dissertations/hill.htm 
 
Table A.4: Fold-change for DE genes after MIR205 transfection. Sheet1: All 9596 
differentially expressed genes between negative controls and transfected HEY cells. 
Sheet2: 593 predicted and down-regulated genes after transfection. 
Please see table on our website: 
http://www.mcdonaldlab.biology.gatech.edu/dissertations/hill.htm 
 
Table A.5: Fold-change for DE genes after MIR419/M12 transfection. Sheet1: All 
6225 differentially expressed genes between negative controls and transfected HEY cells. 
Sheet2: 135 predicted and down-regulated genes after transfection 







SUPPLEMENTARY DATA FOR CHAPTER 3 
 
 
Table B.1: Patient samples analyzed in this study. All tissues were collected according 
to previously published procedures (Bowen, Walker et al. 2009), following approved 
Institutional Review Board protocols from Northside Hospital (Atlanta) and Georgia 






Table B.2: Differentially expressed genes between OSE and EOC. Gene expression 
profiling identified 5910 significantly differentially expressed genes (mRNAs) between 
OSE and EOC. Of these, 2246 (38%) were significantly upregulated and 3664 (62%) 
downregulated in EOC. 
 




Table B.3: Down-regulated transcriptional repressors. Genes belonging to gene 
ontology categories GO:0045892, GO:0000122, GO:0010944, GO:0032088 and 
GO:0008156, relating to the negative-regulation-of-transcription, were downloaded from 
the European Bioinformatics Institute. Down-regulated repressor genes that were also 
predicted microRNA targets formed the 105 transcriptional repressor genes presented in 
this list. 
Probeset_ID Gene-Symbol p-value Fold-change 
230141_at ARID4A 0.00034 -4.29 
209988_s_at ASCL1 0.00612 -4.03 
203232_s_at ATXN1 0.00005 -2.45 
204194_at BACH1 0.00056 -3.65 
236796_at BACH2 0.00371 -3.07 
202391_at BASP1 0.03447 -2.44 
201084_s_at BCLAF1 0.00049 -3.24 
205289_at BMP2 0.00000 -8.73 
207186_s_at BPTF 0.00173 -6.64 
224471_s_at BTRC 0.00011 -2.84 
212914_at CBX7 0.00029 -2.58 
235196_at CDC73 0.00010 -3.72 
209112_at CDKN1B 0.00059 -4.40 
204314_s_at CREB1 0.02689 -2.09 
209674_at CRY1 0.00696 -1.77 
201278_at DAB2 0.00000 -22.47 
200033_at DDX5 0.00936 -3.69 
204602_at DKK1 0.00861 -2.08 
204273_at EDNRB 0.00336 -5.25 
208669_s_at EID1 0.00000 -13.74 
212420_at ELF1 0.03501 -2.80 
203822_s_at ELF2 0.00188 -3.77 
225159_s_at ELK4 0.00242 -2.10 
225417_at EPC1 0.00295 -1.74 
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209455_at FBXW11 0.00119 -2.17 
202949_s_at FHL2 0.00178 -2.83 
226460_at FNIP2 0.00038 -3.13 
218031_s_at FOXN3 0.00383 -2.28 
224891_at FOXO3 0.00195 -2.23 
235444_at FOXP1 0.00000 -5.64 
210002_at GATA6 0.00000 -56.60 
225884_s_at GZF1 0.00700 -2.74 
228813_at HDAC4 0.00098 -2.51 
226648_at HIF1AN 0.00146 -1.96 
219269_at HMBOX1 0.01083 -2.39 
210338_s_at HSPA8 0.00023 -5.40 
201565_s_at ID2 0.01252 -2.02 
209292_at ID4 0.00001 -16.97 
206332_s_at IFI16 0.00000 -7.22 
225798_at JAZF1 0.00009 -2.70 
218486_at KLF11 0.00043 -2.37 
221841_s_at KLF4 0.00021 -5.16 
222561_at LANCL2 0.00009 -2.13 
209348_s_at MAF 0.00000 -10.56 
236814_at MDM4 0.01674 -2.34 
212535_at MEF2A 0.00002 -4.99 
209200_at MEF2C 0.00000 -5.66 
212251_at MTDH 0.00219 -4.70 
219363_s_at MTERFD1 0.00816 -2.04 
212993_at NACC2 0.00055 -4.15 
200854_at NCOR1 0.00233 -1.77 
213012_at NEDD4 0.00008 -1.73 
213032_at NFIB 0.00147 -5.00 
203574_at NFIL3 0.00582 -2.27 
209239_at NFKB1 0.00116 -1.66 
223439_at NKAP 0.01086 -1.99 
209706_at NKX3-1 0.00000 -20.57 
206645_s_at NR0B1 0.00000 -6.22 
212594_at PDCD4 0.00000 -4.50 
210296_s_at PEX2 0.00184 -6.97 
228469_at PPID 0.00001 -2.87 
235764_at PRDM5 0.00000 -7.93 
223275_at PRMT6 0.00698 -2.27 
219485_s_at PSMD10 0.02809 -3.19 
207785_s_at RBPJ 0.00007 -3.50 
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204633_s_at RPS6KA5 0.00353 -1.98 
222540_s_at RSF1 0.06553 -2.57 
203408_s_at SATB1 0.00003 -6.71 
40189_at SET 0.00288 -3.52 
223122_s_at SFRP2 0.00001 -18.40 
218878_s_at SIRT1 0.00108 -2.71 
203076_s_at SMAD2 0.00224 -2.20 
202527_s_at SMAD4 0.00503 -3.04 
206542_s_at SMARCA2 0.00005 -8.79 
211988_at SMARCE1 0.00006 -3.90 
213139_at SNAI2 0.00010 -4.91 
202864_s_at SP100 0.00135 -4.37 
232529_at SP3 0.00021 -5.91 
201996_s_at SPEN 0.01748 -3.31 
201023_at TAF7 0.00019 -2.57 
226037_s_at TAF9B 0.00000 -6.58 
235890_at TBL1XR1 0.00204 -2.42 
225544_at TBX3 0.00178 -3.21 
227705_at TCEAL7 0.00000 -19.44 
204931_at TCF21 0.00043 -3.93 
201730_s_at TPR 0.00958 -4.40 
223393_s_at TSHZ3 0.00000 -5.95 
204771_s_at TTF1 0.01342 -1.90 
208760_at UBE2I 0.00002 -5.03 
220746_s_at UIMC1 0.00029 -2.84 
223118_s_at USP47 0.00015 -4.99 
213425_at WNT5A 0.00000 -7.21 
206067_s_at WT1 0.00146 -3.43 
208643_s_at XRCC5 0.00082 -2.37 
224718_at YY1 0.00076 -2.75 
212764_at ZEB1 0.00019 -4.74 
228333_at ZEB2 0.00020 -2.90 
219778_at ZFPM2 0.00000 -33.39 
223213_s_at ZHX1 0.00380 -2.86 
226015_at ZNF12 0.00036 -4.27 
228545_at ZNF148 0.00001 -6.64 
203247_s_at ZNF24 0.00002 -4.38 
218401_s_at ZNF281 0.00033 -3.48 
225539_at ZNF295 0.00051 -4.22 





Table B.4: Upregulated mutual targets of upregulated miRNAs and down-regulated 
transcriptional repressors. List of 843 TRANSFAC identified targets of 10 repressor 
genes (Table 3.3) that are also targets of one or more of the 31 miRNAs upregulated in 
EOC. 
 








SUPPLEMENTARY DATA FOR CHAPTER 4 
 
Table C.1: Top 5070 differentially expressed genes. This table shows the 5070 
significantly differentially and highly correlated genes, with the fold change (FC) used in 
these analyses. 





Table C.2: The top 350 genes involved in the greatest number of  inconsistent gene-
pair interactions. This table shows the 350 genes involved in the greatest number of 
inconsistent pairings, along with the number of inconsistent interactions. These genes 













VRK1 650 XPR1 645 COL1A2 612 
HELLS 576 TET1 574 CSTF3 558 
SVIL 528 PTPRM 506 RMI1 495 
LRIG1 476 SLCO3A1 464 GPSM2 463 
SLC35E3 447 CHD7 438 HMGB3 430 
COL5A2 419 EZR 398 FAM72A 396 
FAM171A1 395 APOLD1 388 GYG1 367 
C14orf143 365 GUCY1B3 352 PPIC 346 
TFDP1 323 FGFR1OP 322 COL6A3 321 
FCHSD2 310 ANP32E 308 TPM1 307 
ZWILCH 294 BEND3 274 ASPM 272 
HNRNPA1 271 SLC4A7 268 MAD2L1 263 
FNDC3B 257 RPP40 257 PCDHB2 245 
CTHRC1 238 DYRK2 236 PHF16 235 
BTN3A2 232 EIF2C2 231 NETO2 231 
NPAS2 230 THBS2 228 ATAD2 225 
SASS6 225 SPIN4 225 LARP4 222 
CCNA2 221 JPH1 221 SIX4 219 
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GAS5 212 TMCC3 211 CCNB1 210 
ENAH 210 DNA2 209 FANCD2 209 
SCARNA15 208 SPON1 208 TMEM48 208 
TMSB15A 205 MRPL3 199 GALNT2 194 
SELENBP1 194 WWOX 189 NACA 188 
SMG7 188 CHEK1 187 TMEM189 182 
CENPK 178 STMN1 177 HERC6 174 
MYO10 171 RPIA 171 WHSC1 171 
RAD52 169 ZNF738 169 TARBP1 165 
RBPMS 162 COL15A1 161 KIAA1524 161 
FAM119A 159 TBCCD1 159 SRPK1 155 
SMARCC1 154 ADH1B 153 CD59 151 
TRIB2 148 JAG1 145 RNF144B 143 
RUNX1 143 TIA1 142 PCDH7 140 
PXDN 139 BCL2L11 136 PTPRG 136 
CKS1B 132 MEIS1 132 ECT2 130 
PFDN4 129 SLC25A33 129 EFEMP1 128 
HTATIP2 128 FLNC 125 RAB4A 125 
C21orf63 124 GEN1 121 GCLC 120 
KIAA0101 118 SORBS1 117 TOPBP1 116 
CDC16 115 ASAP2 113 HIST1H2AG 112 
ESYT2 111 DLG2 110 XRCC6 109 
NEAT1 105 BICD1 104 FNIP2 104 
BARD1 103 CENPF 102 ZNF439 102 
MTHFD2 100 RAP1GAP2 100 IGDCC4 99 
CASP2 98 EPSTI1 98 KIAA0907 98 
MNS1 96 EPB41L5 95 ADCY7 94 
TMEM178 94 SOAT1 93 GPRC5B 92 
ZDHHC9 91 GINS1 89 CDH6 88 
RAD51AP1 88 C5orf34 87 FAM108C1 87 
TSGA14 87 C15orf27 86 GNB5 85 
CSNK2A1 84 PTPRO 84 PAIP1 83 
CTPS2 82 PRDXDD1P 82 ASAH1 81 
PNO1 81 PRKCI 81 WDHD1 81 
HOXA3 80 B4GALT5 79 CDK1 79 
SMC2 77 COL4A1 76 SMAD1 76 
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PELI1 75 PLK4 75 PUS7 75 
CHSY1 74 TTF2 73 ZNF585A 73 
TMEM37 72 TTC30A 72 DACH1 71 
ITGB8 71 HMMR 70 KRT19 70 
TLR1 70 CD93 69 SETD4 69 
TAGAP 69 VANGL1 69 ANKRD12 68 
GATA5 68 PIAS3 68 SMC4 68 
CFC1 67 CHD2 67 EZH2 67 
LUZP1 67 PHLDA1 67 RNF44 67 
CHCHD7 66 LTBP1 66 TMCO6 66 
C11orf9 65 CASP1 65 N4BP2L2 65 
SAMD9L 65 TIGD1 65 TMEM154 65 
TST 65 UNG 65 GNAS 63 
LRRK2 63 MAML2 63 R3HDM1 63 
SLC16A1 63 HABP4 62 SMCHD1 62 
ZWINT 62 C13orf34 61 C9orf72 61 
DLGAP5 61 IFIT2 61 POMGNT1 61 
QKI 61 R3HCC1 61 TIMELESS 61 
TLR2 61 ASAP1 60 ELF1 60 
HEY2 60 MASTL 60 MIR21 60 
SLC7A11 60 CACNB3 59 COPZ1 59 
OSBPL3 59 SCD 59 TRIP13 59 
ZNF682 59 CHMP2B 58 LRRN4 58 
SNHG12 57 FEN1 56 PHF17 56 
PRC1 56 CD274 55 EIF3M 55 
MAP1LC3B 55 SEMA6A 55 BNIP3L 54 
CD53 54 KAZ 54 MDC1 54 
PLEKHH1 54 XK 53 CBX3 52 
FCGR3B 52 WTAP 52 AURKA 51 
CD83 51 CDV3 51 FGFR1OP2 51 
HCP5 51 KIF11 51 RRAGC 51 
SEC14L1 51 STK17A 51 BBX 50 
CEP55 50 NFIA 50 RILPL2 50 
CASP4 49 CREBL2 49 FAM46A 49 
MMP28 49 MYEF2 49 NEBL 49 
PEA15 49 PRKCB 49 TANK 49 
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COMMD5 48 FOXP1 48 MCM2 48 
NEK6 48 SORL1 48 CNOT2 47 
FNDC1 47 HERC5 47 PTX3 47 
RHOQ 47 METT10D 46 PLLP 46 
SPAG9 46 USP3 46 VCAN 46 
ZNF292 46 DENND1B 45 EIF5 45 
GPR4 45 LITAF 45 PDE4B 45 
PLCG2 45 RAB34 45 SP3 45 
ST3GAL6 45 ZFP82 45 BECN1 44 
CAP1 44 EIF5B 44 ERBB2IP 44 
ESRP1 44 VEZF1 44 ARL6IP5 43 
GPC2 43 LAP3 43 MPZL2 43 
NF1 43 NFIB 43 SLC15A4 43 
SP100 43 TICAM2 43 TNFAIP3 43 
TPP1 43 BRD7 42 COL4A3BP 42 
DSCC1 42 IGF2BP2 42 JMJD1C 42 
LCORL 42 LHFPL2 42 MIR17HG 42 
NPL 42 SFMBT1 42 SKAP2 42 
SLC35A2 42 THBS1 42 CD47 41 
CLCN3 41 EIF5A 41 HMGA2 41 
LARP4B 41 MELK 41 NFIL3 41 
NPEPPS 41 NPY 41 PDLIM5 41 
RNF13 41 RORC 41 SFTPD 41 
SLC1A1 41 SMAD2 41 TMED5 41 
AKR7A2 40 C22orf32 40 CAMK2D 40 
DDX3X 40 IQGAP1 40 KLHL9 40 




Table C.3: The top 350 most significantly differentially expressed genes between 
control and cancer samples. This table shows the 350 most differentially expressed 














ITLN1 -9.29 ALDH1A2 -8.49 LHX2 -8.017 
SFRP1 -7.76 BNC1 -7.45 CHRDL1 -7.317 
LHX9 -7.25 BCHE -7.13 PDGFD -7.062 
ABCA8 -7.01 NELL2 -6.99 SOX17 6.922 
REEP1 -6.89 ADH1B -6.73 EFEMP1 -6.725 
AOX1 -6.68 C13orf36 -6.55 OGN -6.544 
C1orf168 -6.48 ANXA8 -6.45 SLC4A4 -6.391 
RARRES1 -6.32 AQP9 -6.31 TCEAL2 -6.267 
ARHGAP18 -6.24 SPOCK1 -6.23 CD24 6.169 
RAB27B -6.05 C4orf49 -5.94 DSC3 -5.902 
TFPI2 -5.89 TXNIP -5.86 DPYD -5.844 
GATA6 -5.82 FAM153A -5.78 DOCK11 -5.764 
PDE7B -5.73 RGS4 -5.72 WNT2B -5.694 
PRG4 -5.61 MUM1L1 -5.59 KLHL14 5.433 
C8orf84 -5.43 HOXD8 -5.42 FAM70A -5.417 
C21orf62 -5.40 EZR -5.39 SEMA3C -5.333 
DFNA5 -5.33 SLC4A11 5.27 CAV2 -5.272 
ARX -5.27 PSAT1 5.23 SGCG -5.225 
CRNDE -5.21 PCDH17 -5.18 EHF 5.176 
PRKAR2B -5.16 PDE8B -5.14 DCN -5.135 
GAS1 -5.09 LXN -5.08 CYBRD1 -5.074 
ZFPM2 -5.06 FGF13 -5.04 PGR -5.018 
STK31 -5.01 TNFSF13B -4.99 MFSD4 -4.948 
C10orf58 -4.93 MAL 4.93 SLC39A8 -4.913 
GADL1 -4.90 TSPAN5 -4.89 MTUS1 -4.887 
MUC1 4.88 RERG -4.87 CDH6 4.857 
FLRT2 -4.85 MNDA -4.81 ALDH1A3 -4.808 
EMB -4.76 PTGER4 -4.74 SLC2A1 4.742 
KITLG -4.74 S100A2 4.72 CSGALNACT1 -4.672 
ABHD12B -4.61 LGALS2 -4.61 FLRT3 -4.577 
ZIC1 4.56 MMP28 -4.56 SPON1 4.556 
PLSCR4 -4.52 MEIS2 -4.51 NEFH -4.506 
BNC2 -4.50 C2orf40 -4.50 DAB2 -4.490 
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OMD -4.48 GHR -4.47 CRIM1 -4.465 
PROCR -4.45 LGALS8 -4.45 NAP1L3 -4.437 
PAPSS2 -4.43 SYT1 -4.42 CELF2 -4.418 
GPM6A -4.42 CYP3A5 -4.39 SYT4 -4.375 
NKX3-1 -4.36 GABRG1 -4.36 C4orf31 -4.350 
RYR2 -4.33 PRKAR1A -4.32 PTGIS -4.313 
DSE -4.31 PTGER3 -4.29 NUSAP1 4.288 
SNCA -4.28 TCEAL7 -4.28 ECM2 -4.279 
ZWINT 4.27 AIF1L 4.27 PCDH9 -4.252 
PITPNC1 -4.25 PPAP2A -4.24 CENPF 4.241 
STON2 4.23 SCG5 -4.22 KCNJ8 -4.216 
MECOM 4.21 FRY -4.21 KCNT2 -4.202 
SFRP2 -4.20 MPZL2 4.20 USP53 -4.183 
DAPK1 -4.17 CDCA3 4.16 ST7L -4.158 
ANKRD29 -4.16 LIFR -4.15 MST4 -4.142 
EEF1A1 -4.14 IRX3 -4.13 CALB2 -4.116 
CDKN2A 4.11 LRRN4 -4.11 SEMA5A -4.109 
SCD5 -4.10 CTHRC1 4.09 ID4 -4.085 
VIM -4.08 AURKA 4.08 GOLM1 -4.079 
CNTN4 -4.07 KAL1 -4.06 COL3A1 -4.054 
LIPA -4.05 CLIP4 -4.05 MBNL3 -4.041 
LYPLAL1 -4.04 S100A8 -4.03 GPNMB -4.031 
EFNB3 -4.03 OLFML1 -4.03 TIAM1 -4.026 
NBLA00301 -4.02 DTNA -4.02 RTN1 -4.013 
HSD17B2 -4.00 CFL2 -3.99 SLC16A1 -3.985 
SCGB2A1 3.98 CAV1 -3.98 AG2 3.972 
ABI3BP -3.94 CFI -3.94 MCOLN3 -3.937 
PAX8 3.91 DDR2 -3.91 MET -3.906 
NPY1R -3.90 HPGD -3.89 RNF128 -3.884 
NAV3 -3.87 METTL7A -3.87 THBD -3.868 
WFDC2 3.86 CCDC80 -3.86 SGCE -3.849 
GFPT2 -3.85 CNTNAP4 -3.85 LAMA4 -3.833 
CXCR4 3.82 TRIM4 -3.81 SFN 3.796 
ARRDC4 -3.79 PRSS35 -3.79 CLDN1 -3.790 
SNX13 -3.79 RABEP1 -3.79 GSTM3 -3.784 
EID1 -3.78 TPD52L1 -3.78 PPM1K -3.775 
PHACTR2 -3.76 PLCL2 -3.76 SULT1C2 3.746 
RBMS3 -3.74 TFPI -3.74 DPP10 -3.733 
PROS1 -3.72 SLC41A2 -3.71 AKT3 -3.705 
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LIMA1 -3.70 SYBU -3.69 ADH5 -3.692 
HMMR 3.68 CHGB -3.68 SORBS2 -3.678 
NDN -3.67 NBEA -3.67 BAMBI -3.671 
KIAA0101 3.67 PROM2 3.67 RRM2 3.666 
ANXA1 -3.66 VLDLR -3.66 TMTC1 3.659 
UGP2 -3.66 COBLL1 -3.66 SDC2 -3.655 
SNX7 -3.65 C5orf41 -3.65 PTPLA -3.645 
PPM1E -3.64 C13orf33 -3.64 CFH -3.621 
H3F3B -3.62 PMP22 -3.62 GULP1 -3.617 
LSAMP -3.61 SERINC1 -3.60 MSRB3 -3.592 
CP 3.59 C3 -3.59 CAST -3.590 
NAP1L2 -3.59 B2M -3.59 IL18 -3.566 
MTHFD2 3.57 CLK1 -3.56 GALC -3.561 
CARD16 -3.56 AKAP11 -3.55 KIAA1244 -3.552 
PLEKHH2 -3.55 FBXO9 -3.54 HPSE -3.538 
FGF18 3.54 SPOPL -3.53 RAB38 -3.531 
CTNNAL1 -3.52 EPCAM 3.52 GIPC2 -3.502 
UBL3 -3.50 SCP2 -3.48 NR3C1 -3.479 
PHLPP2 -3.48 NR3C2 -3.47 NXPH2 -3.464 
FHL1 -3.46 GNB4 -3.46 FAM89A -3.455 
SQRDL -3.45 RUFY3 -3.45 HMGA1 3.444 
RSPO1 -3.43 TFAP2A 3.43 DMD -3.428 
GRIN2A -3.42 PPP1R3B -3.42 EIF3M -3.417 
ANXA4 -3.42 VCAN 3.41 MGC24103 -3.411 
NTN4 -3.41 CARD16 -3.41 CCNE1 3.408 
TMOD1 -3.41 CLDN15 -3.40 ARHGAP28 -3.403 
MAF -3.40 C1orf186 3.39 PKHD1L1 -3.390 
CFH -3.39 CNRIP1 -3.38 MCTP2 -3.380 
SDPR -3.38 OSTM1 -3.37 FAM13C -3.368 
GCOM1 -3.37 ANXA3 -3.37 PEX5L -3.365 
C8orf4 3.36 C9orf5 -3.36 PCDH7 3.348 
PLCE1 -3.35 RAB31 -3.34 CEP55 3.334 
FBXO3 -3.33 NRXN3 -3.33 ITPR2 -3.329 
NLGN4X -3.32 ESD -3.32 SMAD9 -3.310 
LEPROTL1 -3.31 GPR137B -3.30 CKS2 3.294 
CXXC5 3.29 ME1 -3.29 PKD2 -3.284 
CPE -3.28 MELK 3.28 TGFB2 -3.281 
TRPC1 -3.28 DDX17 -3.28 CMAH -3.276 
SEL1L2 -3.28 CDK1 3.27 LIMS3 3.260 
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PHLDB2 -3.25 KLHDC8A -3.25 CYP39A1 -3.248 
FNDC3A -3.25 RCHY1 -3.25 NEK2 3.240 
ELF3 3.24 FGL2 -3.23 CLEC4M -3.233 
MAOA -3.23 TRPA1 -3.23 NT5DC1 -3.226 
FRAS1 -3.22 CGNL1 -3.21 SIX1 3.213 
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